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ABSTRACT: Developing PROTACs to redirect the ubiquitination activity of E3 ligases and potently degrade a target protein
within cells can be a lengthy and unpredictable process, and it remains unclear whether any combination of E3 and target might
be productive for degradation. We describe a probe-quality degrader for a ligase−target pair deemed unsuitable: the von
Hippel−Lindau (VHL) and BRD9, a bromodomain-containing subunit of the SWI/SNF chromatin remodeling complex BAF.
VHL-based degraders could be optimized from suboptimal compounds in two rounds by systematically varying conjugation
patterns and linkers and monitoring cellular degradation activities, kinetic proﬁles, and ubiquitination, as well as ternary complex
formation thermodynamics. The emerged structure−activity relationships guided the discovery of VZ185, a potent, fast, and
selective degrader of BRD9 and of its close homolog BRD7. Our ﬁndings qualify a new chemical tool for BRD7/9 knockdown
and provide a roadmap for PROTAC development against seemingly incompatible target−ligase combinations.
■ INTRODUCTION
Targeted protein degradation is an emerging strategy to use
small molecules to knock down a protein by hijacking the
ubiquitin−proteasome system.1,2 PROTACs (proteolysis tar-
geting chimeras) are bifunctional degrader molecules composed
of a ligand for the target protein and a ligand for E3 ligase
recruitment, connected by a linker.3,4 Upon formation of a
ternary complex target:degrader:E3,5−7 the protein of interest is
ubiquitinated and degraded by the proteasome. Compared to
target blockade, post-translational protein degradation more
closely phenocopies genetic approaches to target validation and
can lead to a more sustained cellular eﬀect with more extended
duration of action. An attractive feature of PROTACs is their
catalytic mode of action, as any one molecule may perform
multiple rounds of target ubiquitination and degradation.8 A
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consequence of this feature is that degraders can function at
substoichiometric receptor occupancies, meaning they exhibit
degradation activities at concentrations that can be orders of
magnitude lower than their binary dissociation constants (Kd)
from the target, alleviating the requirement for full target
engagement.9 Moreover, PROTACmolecules can add a layer of
target selectivity beyond that expected from the constitutive
binding ligands, thus providing highly selective degraders with
reduced oﬀ-target eﬀect.5,10−12 The mounting interest in
PROTAC drug discovery is also motivated by the promise to
target proteins considered “undruggable” via conventional
medicinal chemistry approaches.13 To date, diﬀerent target
classes have been successfully degraded, including epigenetic
targets such as bromodomain-containing proteins BRD2, BRD3,
and BRD4,5,10,11,14−17 BRD9,18 TRIM24,19 SIRT2,20 PCAF/
GNC5,21 protein kinases,8,12,22−26 nuclear receptors,27,28 and
E3 ubiquitin ligases to self-degrade.29,30
To fulﬁll the potential of targeted protein degradation, a
general methodology for an eﬃcient PROTAC design would be
desirable. However, the development of active PROTAC
degraders is often a laborious and unguided process. The choice
of E3 ligase and the selection of target ligands and their
conjugation are all potential optimization variables that expand
the chemical space to be exploited by medicinal chemists.
Properties of the linker, such as length, composition, and site of
attachment, are known to be important but often their impact on
activity vary in a target- and context-dependent fash-
ion.11,24,29,31,32 Moreover, small-molecule binders for both the
protein of interest and the E3 ligase are required. Despite the
large number of human E3 ubiquitin ligases postulated to
function in cells, only a few have good-quality ligands33 that have
been successfully used for PROTACs.34 The most common
ligases recruited are the von Hippel−Lindau (VHL) protein
complex CRL2VHL and the cereblon (CRBN) complex
CRL4CRBN. Studies have shown that PROTACs made of the
same target ligand but either VHL or CRBN ligands can exhibit
diﬀerent degradation selectivity and eﬃcacy.11,14,18,22 In some
systems, CRBN-based degraders show amore active proﬁle than
VHL-based molecules. Potential greater ﬂexibility of the Cullin4
based CRL4CRBN compared to CRL2VHL has been invoked to
suggest more productive ubiquitination of the accessible lysine
residues on the target protein.1,32,35 These observations would
suggest that the development of VHL-based degraders might
require more exploration in the PROTAC design than those
based on CRBN. Even if degradation of a given target protein
can be readily obtained by recruiting one E3 ligase, emerging
evidence suggests that it could be beneﬁcial to develop a parallel
chemical series hijacking other E3 ligases. For example, chemical
liabilities on a particular ligase ligand could be readily
circumvented by switching to a diﬀerent compound. The
hijacked E3 ligase expression and intrinsic activity may be
context-dependent, and vary widely among diﬀerent cells and
tissue types.36 Furthermore, resistance mechanisms could
potentially arise from the loss of the hijacked E3 ligase, as
demonstrated by the correlation between level of CRBN and
response to CRBN-recruiting drugs in multiple myeloma.37
Switching the hijacked ligase can thus aid targeted protein
degradation. It however remains unclear whether optimal
target−E3 pairs exist or indeed whether any combination of
E3 ligase and target protein might be tractable.
Here, we demonstrate the development of probe-quality
PROTACs for a ligase−target pair previously considered
incompatible: VHL and the protein BRD9.18 BRD9 and its
close homolog BRD7 (85% sequence identity38) are bromodo-
main-containing subunits of the BAF (BRG-/BRM-associated
factor) and PBAF (polybromo-associated BAF) complexes,
respectively.39,40 BAF and PBAF represent two variants of the
SWI/SNF complex, one of the four mammalian ATP-dependent
chromatin remodeling complexes. The SWI/SNF complexes
control gene expression, DNA replication, and DNA repair by
modulating access to promoters and coding regions of DNA
through modiﬁcation of the degree of compactness of
chromatin.41−43 Mounting evidence from genetics and sequenc-
ing of cancer-associated mutations have spurred eﬀorts to
unravel yet largely elusive physiological roles of BAF/PBAF
subunits and to develop targeted therapeutics in cancer and
other human diseases.39 In particular, BRD9 is overexpressed in
several malignancies, such as cervical cancer and in non-small-
cell lung cancer (NSCLC).44,45 In contrast, BRD7 gene has been
proposed as candidate tumor suppressor gene,46−49 as it
regulates breast cancer cell metabolism50 and acts as negative
regulator of aerobic glycolysis essential for tumor progression.51
BRD7 also promotes X-box binding protein 1 (XBP1) nuclear
translocation, which prevents the development of insulin-
resistance disorders.52 In contrast to these roles, it has been
recently shown that inactivation of the BRD7 gene sensitizes
tumor cells to T cell-mediated killing, suggesting that knock-
down of BRD7 could be an attractive target for cancer
immunotherapy.53 Potent and selective inhibitors that bind to
the BRD7/9 bromodomains have recently emerged from
structure-guided medicinal chemistry campaigns, including
compounds I-BRD9,38 LP99,54 ketone “compound 28”,55 BI-
7273 and BI-956456 (1a,b, Figure 1), and GNE-375.57 These
BRD7/9 inhibitors have been used in cells to help clarify the
roles of the BRD7/9 bromodomains in oncogenesis and other
disease states. For example, pharmacological studies of
inhibitors 1a and 1b in combination with domain-swap protein
engineering revealed that an active bromodomain of BRD9 is
required to sustain MYC transcription and proliferation of
Figure 1. Chemical structures of parent (1a, 1b, 2−4) and modiﬁed
(1c, 2a−4a) BRD7/9 and E3 ligase ligands. Functional groups selected
for conjugation are shown in blue on parent ligands and in red on
modiﬁed ligands.
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Scheme 1. Synthesis of the BRD7/9 Ligand 1ca
aReagents and conditions: (a) 1-Boc-piperazine, NaBH(OAc)3, THF, rt, overnight, yield 97%; (b) NaH, CH3I, DMF, 0 °C, 5 h, yield 95%. (c)
Step 1: 12, B2pin2, KOAc, Pd(dppf)Cl2, 1,4 dioxane, microwave, 140 °C, 40 min. Step 2: 14 and K2CO3 (aq) are added to step 1; microwave, 120
°C, 30 min, yield 55%. (d) HCl 4 M in dioxane, DCM, rt, 1 h, quantitative yield.
Scheme 2. Synthesis of the First Generation of Degradersa
aReagents and conditions: (a) oxalyl chloride, DMSO, DCM, then TEA, −78 °C to rt, 2 h; (b) 1c, NaBH(OAc)3, TEA, DMF, rt, overnight; (c)
TFA, DCM, rt, 2 h; (d) E3 ligand (2a, 3a, or 4a), HATU, HOAt, DIPEA, DMF, rt, 2 h.
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leukemic cells.56,58 These ﬁndings and availability of bromodo-
main ligands prompted us to initiate a PROTAC medicinal
chemistry campaign to target BRD7 and BRD9 proteins for
degradation.
■ RESULTS AND DISCUSSION
First Generation of BRD7 and BRD9 Degraders. We
began our investigation by designing a small set of PROTACs
aimed to induce BRD7/9 degradation by recruiting three
diﬀerent E3 ubiquitin ligases: VHL, CRBN, and DCAF15.59,60
We aimed to leverage available E3 ligase ligands and tomaximize
the opportunity for complementary surfaces between the
bromodomain and the ligase within the ternary complex. As
BRD7/9 bromodomain ligands, we selected compounds 1a,b
(Figure 1),56 on the basis of their high binding aﬃnity56 and of
their superiority as BRD9 chemical probes over other ligands.58
To design the ﬁrst generation of degraders, we inspected the
crystal structure of 1a bound to BRD9 (PDB code 5EU1)56 to
identify suitable attachment points and vectors for linker
conjugation, important considerations for PROTAC design as
known to greatly inﬂuence degradation activities.11,29 The
dimethylamine group of themolecule was identiﬁed as a solvent-
exposed group not involved in interactions with the protein. For
synthetic reasons, the dimethylamine group of compound 1a
was replaced by a piperazine group (BrdL1 (1c), Figure 1 and
Supporting Information Figure S1), providing a convenient
isosteric handle. As E3 ligase recruiting moieties, VH032 (2,
VHL ligand, Figure 1)61−63 and pomalidomide (3, CRBN
ligand, Figure 1)64 were selected and modiﬁed to aﬀord
compounds VHL1 (2a) and 3a (Figure 1 and Supporting
Information Figure S1). The amino terminal groups of 2a and 3a
were conjugated via amide bond to the linker without perturbing
the interaction with the E3 ligases, as previously demonstra-
ted.8,10,15,22 To expand the arsenal of E3 ligase ligands being
explored, we designed conjugates containing indisulam (4,
Figure 1), a small molecule recently reported to bind to the E3
ligase DCAF15 and to redirect the activity of the CRL4DCAF15
complex toward the neosubstrate CAPERα (also known as
RBM39).59,60 As the binding mode of 4 is not known, we
leveraged information on the activity of a biotinylated
photoactive analogue probe to guide our conjugation strategy.60
Accordingly, a para-benzylamine analogue of 4 (derivative 4a,
Figure 1 and Supporting Information Figure S1) was designed as
conjugatable ligase ligand. To generate a ﬁrst set of compounds,
we decided to use PEG linkers composed of two or four PEG
units to connect the two warheads (compounds 5−10, Scheme
2).
Compounds 5−10 were obtained as reported in Schemes 1
and 2. Brieﬂy, reductive amination between the commercially
available 4-bromo-2,6-dimethoxybenzaldehyde (11) and boc-
piperazine led to the formation of compound 12 which was then
cross-coupled with 14 (obtained by methylation of 13) under
theMyaura−Suzuki condition (one-pot two steps); the cleavage
of tert-butyloxycarbonyl protecting group in acidic conditions
aﬀorded 1c in quantitative yield (Scheme 1). The primary
alcohol functionality of the linkers (15 and 16) was oxidized to
aldehyde group using a Swern reaction and condensed with the
terminal secondary amine of 1c to aﬀord the tert-butyl ester
intermediates 17 and 18 that were converted into the
corresponding acids by triﬂuoroacetic acid (TFA) treatment
(Scheme 2). Compounds 19 and 20 were then conjugated with
the conjugatable E3 ligands (2a and 3a prepared as previously
described,61,65 and 4a synthesis in Supporting Information
Synthetic Procedures) using HATU as coupling reagent yielding
ﬁnal compounds 5−10.
Figure 2. Screening of ﬁrst generation of degraders. (A) Western blot analysis of BRD9 and BRD7 levels after treatment of HeLa cells with 1 μM
compounds for 4 and 16 h before harvesting. Degradation activity is reported below each lane as % of protein abundance relative to 0.1% DMSO
vehicle. (B) Western blot analysis of BRD9 and BRD7 levels after 48 h transfection with 1.25 nM siRNA targeting respectively BRD7, BRD9, or
negative control (N.C.) siRNA. Intensity values are quantiﬁed as described in the Experimental Section.
Figure 3. Structures of compounds 7 and 21.18
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To assess the degradation activity of the ﬁrst generation of
PROTACs, HeLa cells were treated with compounds 5−10 at
ﬁxed concentration of 1 μM, for 4 and 16 h before harvesting
(Figure 2A). CRBN-based PROTACs 7 and 8 demonstrated
strong degradation of BRD9 already after 4 h of treatment,
whereas no BRD7 degradation was observed (Figure 2A). In
contrast, VHL-based degraders 5 and 6 showed weak activity
against both BRD7 and BRD9, inducing at most 20%
degradation after 4 h and 30% after 16 h, and even weaker
activity was observed with the indisulam-based PROTACs 9 and
10 (Figure 2A). siRNA knockdown experiments (Figure 2B)
validated the speciﬁcity of the bands observed by Western blot.
While this research was underway, Remillard et al.18 disclosed
the BRD9 degrader dBRD9 (21, Figure 3) conﬁrming the strong
degradation activity of our CRBN-recruiting PROTACs.
Compounds 7 and 21 share the same target and E3 ligands,
which, however, were diﬀerently modiﬁed to attach two distinct
linkers (Figure 3). CRBN-based PROTACs, however, can
exhibit oﬀ-target degradation of non-PROTAC-targets such as
IKZF1/3 and GSPT1 due to the neomorphic activity of the
CRBN ligand alone.18,66
We therefore turned our attention to VHL-based PROTACs.
Encouraged by the degradation, albeit partial, of both BRD7 and
BRD9 induced by our initial VHL-based PROTACs, we decided
to characterize the binding of 5 biophysically and structurally.
To determine the binding mode of the conjugated bromodo-
main ligand, compound 5 was cocrystallized with the BRD9
bromodomain (BRD9-BD). In the BRD9-BD:5 complex, the
bromodomain ligand was clearly observed within its binding
pocket, and its binding mode closely recapitulates that of 1a
(rmsd = 0.569 Å) (Figure 4A,B). The alkylated piperazine is
favorably accommodated within the binding site, with the linker
directed toward solvent, as desired (Figure 4A,B).
To characterize biophysically the interplay between VCB
(VHL-ElonginC-ElonginB complex), compound 5, and the
BRD9 bromodomain, we applied our previously developed ITC
assay5,11 that measures the thermodynamics and cooperativities
of ternary complex formation. Previous work has demonstrated
that VHL is capable of forming highly stable and cooperative
ternary complexes, as seen with MZ1-Brd4BD2 (ref 5) and with
the homo-PROTAC dimerizer CM11 (ref 29). Titrations of
protein into PROTAC alone revealed a binary binding aﬃnity
Figure 4. Ternary complex formation and analysis of binding mode for compound 5. (A) Cocrystal structure of BRD9-BD and compound 5. The
warhead component of the degrader (purple and cyan; one from each protomer in the ASU) recapitulates the binding of inhibitor 1a (magenta, PDB
code 5EUI),56 whereas the alkylated piperazine used to attach the linker is solvent-exposed and does not form any unfavorable interactions with the
protein. (B) Fo − Fc omit map of compound 5 (contoured at 2.5σ) showing electron density for the alkylated piperazine ring. (C) BRD9-BD titrated
into 5 alone. (D) VCB titrated into 5 alone. (E) VCB titrated into BRD9-BD:5 binary complex. VCB binds more weakly to the binary complex BRD9-
BD:5 (Kd = 73 nM) compared to compound 5 alone (Kd = 33 nM), indicating negative cooperativity.
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for VCB (Kd = 33± 2 nM, Figure 4D and Table 1) within 2-fold
of that measured on previously characterized VHL-based BET
degrader MZ1 (Kd = 70 nM, refs 5 and 11). Similarly, the binary
aﬃnity (Kd = 15 ± 3 nM) and binding enthalpy (ΔH = −12
Table 1. Thermodynamic Parameters of Formation of Binary and Ternary Complexes between VCB, BRD9 Bromodomain, and
Compound 5 Measured by Isothermal Titration Calorimetry (ITC)a
syringe cell Kd (nM) ΔH (kcal/mol) ΔG (kcal/mol) −TΔS (kcal/mol) N α
BRD9-BD 5 15 ± 3 −12.5 ± 0.4 −10.7 ± 0.1 1.8 ± 0.5 0.753 ± 0.004
VCB 5 33 ± 2 −15.2 ± 0.1 −10.2 ± 0.1 4.9 ± 0.1 0.60 ± 0.01
BRD9-BD:5 73 ± 2 −6.4 ± 0.1 −9.7 ± 0.1 −3.3 ± 0.1 0.75 ± 0.05 0.45
aAll ITC titrations were performed at 25 °C. Values reported are the mean ± SEM from at least three independent measurements (n ≥ 3).
Table 2. SAR of Second Generation of PROTACsa
aFootnote: *Degradation activity reported as % of total protein remaining after 1 μM compound treatment relative to 0.1% DMSO vehicle as
quantiﬁed by Western blotting of HeLa cell lysates.
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kcal/mol) for BRD9-BD (Figure 4C and Table 1) were
comparable to that of inhibitor 1a,56 consistent with the
conserved binding modes of 5 and inhibitor 1a observed
crystallographically (Figure 4A). The titrations of VCB into
BRD9-BD:5 complex (Figure 4E) showed that VCB binds more
weakly to the binary complex BRD9-BD:5 (Kd = 73 nM) than to
compound 5 alone (Kd = 33 nM), indicating negative
cooperativity (α < 1, Table 1). Negative cooperativity has
previously been observed with tetrahydroquinoline-based BET
PROTACs, where it was demonstrated that linker length and
exit vector can signiﬁcantly inﬂuence ternary complex
formation.11 On the basis of these considerations, we reasoned
to explore variations on the linker as well as the point of
derivatization.
Second Generation of BRD7 and BRD9 Degraders. To
improve ternary complex formation and degradation activity of
PROTACs 5 and 6, we explored the impact of varying their
derivatization point, linker length, and composition (com-
pounds 22−31, Table 2). First, to expand the conjugation
pattern between VHL1 and BrdL1 (Figure 1), the number of
PEG units was modiﬁed (3 units for 24; 5 units for 22), a more
lipophilic 11-atoms chain was inserted (compound 23), and a
diﬀerent attachment to BrdL1moiety via amide conjugation was
explored (compound 25) (Table 2). Furthermore, we explored
a conjugation vector via a phenolic position (VHL2 (2b),
compounds 28 and 31, Table 2 and Supporting Information
Figure S1), as previously described.29,67 To improve binary
binding aﬃnities to VHL and potentially ﬁne-tune intermo-
lecular interactions in the ternary complex,5 we replaced the
VHL2 acetyl group with either a cyanocyclopropyl group
(VHL3 (2c), derivatives 27 and 30, Table 2 and Supporting
Information Figure S1)29,62 or a ﬂuorocyclopropyl group
(VHL4 (2d), derivatives 26 and 29, Table 2 and Supporting
Information Figure S1).63 As assessed by crystallographic
studies (for 2c, PDB code 5LLI; for 2d, PDB code 5NVX),
these modiﬁcations accommodate snugly on the VHL protein
surface and enhance binding aﬃnity.62,63 To allow direct
comparison with the compounds from the ﬁrst series,
compounds 26−28 and 29−31 were designed to contain
PEG2 and PEG4 linkers, respectively.
Scheme 3. Synthesis of Compound 23a
aReagents and conditions: (a) NaH, 6-bromo-1-hexene, DMF/THF, rt, overnight; (b) BAIB, TEMPO, ACN/H2O, rt, overnight; (c) 2a, HATU,
HOAt, DIPEA, DMF, rt, 2 h; (d) OsO4 4 wt % in H2O, NaIO4, pyridine, dioxane/H2O, rt; (e) 1c, NaBH(OAc)3, TEA, DMF, rt, overnight.
Scheme 4. Synthesis of Compounds 26−31a
aReagents and conditions: (a) NaOH, allyl bromide, dioxane, rt, overnight; (b) MsCl, TEA, DCM, rt, 3 h; (c) VHL ligands 2b−d, K2CO3, DMF,
70 °C, overnight; (d) OsO4, NaIO4, pyridine, dioxane/H2O, rt; (e) 1c, NaBH(OAc)3, TEA, DMF, rt, overnight.
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Compounds 22 and 24 were obtained via the same synthetic
route used for the ﬁrst generation (synthesis of compounds 22,
24, and 25 detailed in the Supporting Information). The
synthesis of 23 (Scheme 3) involved nucleophilic attack of
diethylene glycol (PEG2) to 6-bromo-1-hexene to aﬀord
derivative 33 that was oxidized to carboxylic acid 34 by
treatment with TEMPO and bis-acetoxyiodobenzene (BAIB).
After coupling with 2a, Lemieux−Johnson oxidation of the
double bond yielded the aldehyde intermediate that was reacted
with amine 1c to yield compound 23 in 54% yield. A similar
synthetic strategy was applied for the synthesis of degraders 26−
31 (Scheme 4). Brieﬂy, after nucleophilic substitution of
polyethylene glycol (PEG2 and PEG4) with allyl bromide, the
alcoholic group of 38 and 39 was activated as mesylate and
reacted with the phenolic group present in the VHL ligand
scaﬀold aﬀording derivatives 40−45. The alkene moiety was
then oxidized, and the resulting aldehyde derivative was directly
used for the ﬁnal reductive amination step with 1c to aﬀord the
ﬁnal products 26−31.
All second-generation compounds were proﬁled for BRD9
and BRD7 degradation after treatment for 4 and 16 h (Figure 5A
and Supporting Information Figures S2 and S3). The two VHL-
based PROTACs 5 and 6 were included as reference
compounds. Derivative 26 (Figure 5B) demonstrated marked
and selective (around 90%) depletion of BRD9 over BRD7
already after 4 h treatment inHeLa cells (Figure 5A, Table 2). By
comparing and contrasting the degradation proﬁles of related
compounds, structure−activity relationships began to emerge
(Table 2). As expected, the length of linkers inﬂuenced
degradation proﬁles, with more pronounced BRD9 degradation
observed with shorter linkers for given matched pairs (compare
26 and 29; 27 and 30; 5 with 24, 6, and 22). We also observed
that for a given linker length, replacement of an oxygen atom
with a methylene group was beneﬁcial to degradation activity
(compare 23 vs 24). Among conjugates derivatized at the
phenolic position of the VHL ligand, the nature of the terminal
capping group also inﬂuenced degradation potency. Within each
series of conjugates of ﬁxed linker, compounds bearing the
ﬂuorocyclopropyl moiety (VHL4) were more potent degraders
than those containing cyanocyclopropyl (VHL3) and evenmore
so than acetyl group (VHL2) (26 vs 27 and 28; and 29 vs 30 and
31, respectively) (Table 2). These trends are consistent with the
binary binding aﬃnity values measured for the corresponding
VHL ligands.63 To account for potential diﬀerent protein
expression levels, compounds 22−31 were tested across a panel
of diﬀerent cancer cell lines (Supporting Information Figures S2
and S3). From these degradation screens, 26 was conﬁrmed as
the most active compound, consistently across all assays and cell
lines.
Compound 26 was further characterized by proﬁling its
concentration-dependent activity at early time points (30 min
and 4 h before harvesting; Figure 5C and Supporting
Information Figure S4). PROTAC 26 induced preferential
degradation of BRD9 over BRD7, resulting in a half-degrading
concentration (DC50) of 560 nM against BRD9 (Figure 5C and
Supporting Information Figure S4). More than 60% of
degradation of BRD9 was observed at 1 μM after 4 h, while
maximal degradation (Dmax around 80%) was reached at 10 μM.
At higher doses, the characteristic “hook eﬀect” was observed,
consistent with 26 acting preferentially as inhibitor over
degrader at high concentrations. Rapid and selective target
degradation was conﬁrmed by proﬁling cellular activities over
time (Figure 5D and Supporting Information Figure S4).
Treatments of HeLa cells at ﬁxed concentration (1 μM) of 26 at
varying time points revealed rapid degradation of BRD9 with an
apparent half-life of 3.5 h, resulting in more than 50%
Figure 5.Compound 26 induces rapid and profound depletion of BRD9 in cells. (A)Western blot analysis of BRD9, BRD7, and β-actin after treatment
of HeLa cells with 1 μM compounds for 4 h before harvesting (data reported in Table 2). (B) Chemical structure of 26. (C) Quantiﬁcation of BRD9
protein levels after treatment of HeLa with six diﬀerent concentrations of 26 at 30 min and 4 h before harvesting. (D) Quantiﬁcation of BRD9 protein
levels after treatment with 1 μM 26 in HeLa at the desired time points. Intensity values, DC50, and half-lives were quantiﬁed as described in the
Experimental Section.
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degradation already after 4 h treatment and achieving the
highest level of depletion after 8 h (Figure 5D).
To determine to what extent a correlation could be seen
between ternary complex formation and the improved
degradation properties of 26, we turned to measurements of
thermodynamic parameters and cooperativity by ITC (Figure
6A and Supporting Information Figure S5). Titrating VCB into
26 alone or BRD9-BD:26 complex indicated a cooperativity α =
1, an over 2-fold improvement over 5. At the binary level
compared to 5, we observed negligible diﬀerence between 26
and 5 in binding aﬃnity for BRD9-BD, but a slight loss in aﬃnity
for VCB (Kd = 87 ± 5 nM for 26 compared to 33 ± 2 nM for 5)
(Supporting Information Table S1).
To conﬁrm these ﬁndings, we repurposed an existing
ﬂuorescence polarization (FP) assay that involves the
competitive displacement of a FAM-labeled HIF-1α peptide.68
By comparing PROTAC-induced peptide displacement in the
presence and absence of BRD9-BD, it is possible to determine
the cooperativity (Figure 6B,C). FP measurements for
compound 5 showed a rightward shift in the IC50 curve in the
presence of BRD9-BD, indicating negative cooperativity,
whereas compound 26 showed no shift. Back-calculation of Kd
values63 produced aﬃnity values that were comparable to those
obtained by ITC (Supporting Information Table S1 and Figure
S5).
Previous studies with VCB and BET bromodomains have
demonstrated that the amount of ternary complex formed is well
correlated to the cooperativity of the system.5 Therefore, we
employed an AlphaLISA proximity assay to determine the eﬀect
of increasing cooperativity on ternary complex formation
(Figure 6D). Indeed, there was a 50% increase in the maximum
α intensity measured for VCB:26:BRD9-BD compared to
VCB:5:BRD9-BD, suggesting that the increased cooperativity of
26 compared to 5 resulted in increased population of ternary
complex.
Third Generation of BRD7 and BRD9 Degraders. The
pronounced degradation of BRD9 observed with 26 motivated
us to design a third generation of PROTACs with the goal to
further optimize our degrader. On the basis of the SAR
previously acquired, the design strategy was to keep VHL4
moiety ﬁxed and to focus on systematically varying the linker
length and composition, as well as the substitution and
conjugation chemistry at the BRD7/9 warhead. The focus on
the linker concentrated on exploring varying ratios between
hydrophilic and lipophilic portions within the context of three
diﬀerent lengths: 5, 8, and 11 atoms (Table 3). We reasoned that
varying the balance between hydrophilicity and lipophilicity
might inﬂuence the conformational equilibria and intrinsic
folding propensity of the linker, with direct impact on the
process of ternary complex formation as well as potentially cell
permeability. Linkers were connected to four diﬀerent analogues
of BRD7/9 ligands. Guided by the structure−activity relation-
ships of BRD7/9 bromodomain inhibitors developed by Martin
et al.,56 we introduced two structural variations, single or in
combination. First, we arranged the methoxy groups on the
phenyl ring in either meta (BrdL1, 1c) or para (BrdL2, 1d)
(Table 3 and Supporting Information Figure S1) relative to each
other. Second, we replaced the piperazine moiety with an
azetidine group (BrdL3, 1e and BrdL4, 1f, Table 3 and
Supporting Information Figure S1). For conjugation between
the bromodomain ligand and the linker, either tertiary amines
(via reductive amination reactions) or amide bonds were
contemplated. This design yielded a set of 19 new PROTACs
(Table 3).
To circumvent the need to use the hazardous reagent osmium
tetroxide previously applied in the Lemieux−Johnson reaction,
some key modiﬁcations and optimization to the synthesis were
made (Scheme 5 and Supporting Information Synthetic
Procedures). Mesylation of the free hydroxy group of the
linkers allowed nucleophilic attack by the phenolic group of 2d
Figure 6. Improved ternary complex formation by series-2 degraders. (A) Overlay of compound 26 titrations shows no diﬀerence between binary
(VCB into 26 alone; black) and ternary (VCB into BRD9-BD:26 binary complex; green) titrations. (B) Fluorescence polarization measurements for
compound 5 in the presence (red) and absence (black) of BRD9-BD. The rightward shift in the presence of BRD9-BD indicates negative cooperativity.
Each point is the mean ± SEM of at least two individual experiments performed in triplicate. (C) Fluorescence polarization measurements for
compound 26 in the presence (green) and absence (black) of BRD9-BD. Each point is the mean ± SEM of at least two individual experiments
performed in triplicate. (D) AlphaLISA assay showing increased ternary complex formation for 26 (green) compared to 5 (red). Each point is themean
± SEM of at least one experiment performed in quadruplicate.
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Table 3. SAR of Third Generation of PROTACsa
aFootnote: *Degradation activity reported as % of total protein remaining after 1 μM compound treatment relative to 0.1% DMSO vehicle as
quantiﬁed by Western blotting of HeLa and RI-1 cell lysates.
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(Scheme 5). The lipophilic compound 66, instead, was
conjugated to 2d via alkylation (Scheme 5). Then, the diacetal
functional group on the linker was hydrolyzed to aldehyde under
acidic conditions to allow reductive amination with 1c,d
(synthesis of 1d is described in the Supporting Information)
warheads, leading to the formation of compounds 46−54. To
conjugate the linker to 1e,f via amide bond, VHL-linker
aldehyde intermediates were oxidized to acid through a Pinnick
reaction. Then, HATU-mediated coupling with 1e,f (synthesis
described in the Supporting Information) was applied to obtain
the ﬁnal compounds 55−64 (Scheme 5 and Supporting
Information Synthetic Procedures).
Degraders 46−64 were screened at 1 μM in HeLa cells
following 4 and 16 h of treatment (Table 3, Figure 7A and
Supporting Information Figure S6). A large proportion of
compounds induced eﬃcient degradation of both BRD7 and
BRD9 in HeLa cells, with less than 10% total protein remaining
after 4 h treatment (Table 3, Figure 7A). Overall, within
matched pairs, greater degradation activity was observed for
compounds containing meta (BrdL1 and BrdL3) over para
(BrdL2 and BrdL4) dimethoxy substituents (as representative
examples: 46 vs 47, 26 vs 48, 51 vs 52, Figure 7A). To assess
consistency of cellular activity, compound screening was
repeated in RI-1 (DLBCL) cells after 2 h of treatment (Table
3, Figure 7B). This cell line was chosen because it is sensitive to
BRD9 inhibition,58 it is of clinical relevance, and it also expresses
both VHL and CRBN ligases (Supporting Information Figure
S7). The compounds that induced greatest protein degradation
activity after 2 h were 46 and 52 (on BRD9), and 51 (on BRD7)
(Figure 7B). Compounds 46 and 51 diﬀer only by one atom in
Scheme 5. General Synthetic Routes for Third-Generation Compoundsa
aReagents and conditions: (a) MsCl, TEA, DCM, rt, 3 h; (b) 2d, K2CO3, DMF, 70 °C, overnight; (c) K2CO3, DMF, 70 °C, overnight; (d) HCl 1
N, THF (1:1), 50 °C, 2 h; (e) 1c,d, NaBH(OAc)3, TEA, DMF, rt, overnight; (f) Na2HPO4, NaClO2, 2-methyl-2-butene, t-BuOH, H2O, rt, 4 h ;
(g) 1e,f, HATU, HOAt, DIPEA, DMF, rt, 2 h.
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the center of the linker, which is oxygen or carbon, respectively
(Table 3). Compound 52 is the analogue of 51 but with BrdL2
instead of BrdL1 (Table 3). 46 and 51 showed enhanced
degradation of BRD9 compared to 26, and similar levels of
degradation compared to CRBN-based degrader 7 in RI-1 cells
after 8 h treatment. In addition, 46 and 51 achieved PROTAC-
induced degradation of BRD7 in addition to BRD9 (Figure 7C).
We next decided to assess the concentration-dependent
activity of 46 and 51 in RI-1 cells at two time points (2 and 8 h)
after treatments at diﬀerent concentrations (Figure 8A,C). This
experiment revealed 51 to be the most potent of the two,
achieving maximal protein degradation of BRD9 in the 10−100
nM window, and of BRD7 between 0.1−1 μM, with the hook
eﬀect observed at higher concentrations with both proteins
(Figure 8A). In contrast, 46 required concentrations of about
10-fold higher than 51 to achieve its Dmax, and consequently
longer treatment times to achieve similar degradation levels of
both BRD9 and BRD7 (Figure 8A). Dose-dependent
degradation proﬁles of 51 at the 8 h time-point gave half-
degrading concentrations (DC50) of 1.76 nM and 4.5 nM against
Figure 7. Screening of third generation of degraders. (A) Western-blot analysis of BRD9 and BRD7 levels after treatment of HeLa cells with 1 μM
compounds for 4 h before harvesting. (B) Western blot analysis of BRD9 and BRD7 levels after treatment of RI-1 cells with 1 μM compounds for 2 h
before harvesting. (C) Western blot analysis of BRD9 and BRD7 levels after treatment of RI-1 cells with 1 μM 7, 26, 46, and 51 for 2 and 8 h before
harvesting. Intensity values were quantiﬁed as described in the Experimental Section.
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BRD9 and BRD7, respectively (Figure 8C). The pronounced
hook eﬀect observed on BRD9 protein levels upon treatment
with 1 μM of 51 (Figure 8A,C) explains its apparent weaker
degradation activity in the initial screening (Figure 7B). The
potent and rapid protein degradation induced by 51 was
conﬁrmed by assessing its activity in RI-1 cells treated with 10
nM or 100 nM of compound at varying time points (Figure 8D).
Levels of both BRD7 and BRD9 decreased by more than 50%
already after 30 min of treatment at 100 nM, reaching more than
90% of degradation after 4 h. No protein recovery was observed
through 48 h of treatment. At the lower concentration used (10
nM) 51 was seen to degrade preferentially BRD9 over BRD7,
consistent with the lower DC50 value for BRD9 versus BRD7.
Together, the results of the stepwise design and optimization of
VHL-based degraders allowed us to identify 51 as our most
potent degrader, with DC50 in the single-digit nanomolar range
Figure 8. VZ185 induces strong and rapid degradation in a time- and dose-dependent manner. (A)Western blot analysis of BRD9, BRD7, and β-actin
after treatment of RI-1 cells with six diﬀerent concentrations of compounds 46 and 51 for 2 and 8 h before harvesting. (B) Chemical structures of 51
(VZ185) and 46. (C) Quantiﬁcation of protein levels relative to DMSO control after treatment with diﬀerent concentration of VZ185 and DC50
values. (D) Time-dependent experiment in RI-1 cells after treatment with 10 nM and 100 nM 51 at the desired time points. Intensity values and DC50
were quantiﬁed as described in the Experimental Section.
Figure 9. Quantitative live-cell kinetics of VZ185 induced degradation of BRD7 and BRD9. Degradation proﬁle (A), calculation of DC50 values (B),
and initial degradation rate (C) across concentration series indicated of VZ185 using continual luminescent reading of CRISPR/Cas9 endogenously
tagged HiBiT-BRD7 or HiBiT-BRD9 in HEK293 cells. Error bars are expressed as SEM taken from n = 3 experiments.
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and profound Dmax greater than 90% (Figure 8). These data
qualiﬁed PROTAC 51 as a potent dual BRD9 and BRD7
degrader, hence afterward referred to as VZ185.
To conﬁrm the potent and rapid degradation activity of
VZ185 and its superiority over close analogues, we employed
orthogonal kinetic degradation studies using live cell lumines-
cent monitoring of BRD7 and BRD9 endogenously tagged with
HiBiT in HEK293 cells using CRISPR/Cas9.69 Degradation
proﬁle experiments carried out over 24 h conﬁrmed the superior
degradation activity of VZ185 over compounds 26 and 46 at a
ﬁxed concentration of 1 μM (Supporting Information Figure
S8). Treatment across a range of concentrations of VZ185 of
both HiBiT-BRD7 and HiBiT-BRD9 revealed diﬀerential
degradation proﬁles (Figure 9A) and allowed the calculation
of Dmax, DC50 values, and initial rates of degradation (Figure
9B,C). Indeed, rapid degradation was observed within a few
hours by VZ185 showing preference for BRD9 as compared to
BRD7 (BRD9-DC50 = 4 nM; BRD7-DC50 = 34 nM) (Figure
9B). Degradation rate was directly proportional to the
concentration of VZ185 except at high concentration for
BRD9where the curve reaches a plateau (Figure 9C). This trend
was in line with the strong “hook eﬀect” previously observed
with VZ185. Degradation activity was also conﬁrmed within
matched-pairs 26−48 and VZ185-52 with CRISPR/Cas9-
mediated HiBiT endogenous tagging of BRD9 and BRD7 in
HEK293 cells (Supporting Information Figure S8). In addition,
degradation analysis in a panel of other human cancer cell lines
(EOL-1, A-204) conﬁrmed the potency of VZ185, showing a
DC50 between 2 and 8 nM for BRD9 (Supporting Information
Figure S9).
Following its identiﬁcation as the best degrader, we subjected
VZ185 to a thorough biophysical characterization in order to
dissect the molecular basis underpinning its potent degradation
activity. Both the ITC and FP data indicated that the PROTAC
was not more cooperative than 26 (Table 4 and Supporting
Information Figures S5 and S10). Consistent with this, the
amount of ternary complex estimated by AlphaLISA was also
not signiﬁcantly diﬀerent from that measured for 26 (Table 4
and Supporting Information Figure S10). However, the binary
aﬃnity for both VCB (Kd = 26 ± 9 nM) and the BRD9
bromodomain (Kd = 5.1± 0.6 nM)was signiﬁcantly greater than
26. The pronounced binary aﬃnity for each respective protein
provides some basis for the strong “hook eﬀect” observed in the
degradation assays, consistent with previous reports that a high
binary aﬃnity can direct PROTACs to function preferentially as
inhibitors at higher concentrations and exhibit strong hook
eﬀects.11 Despite the absence of a signiﬁcant boost in
cooperativity over 26, the total ΔG° for ternary complex
formation increased to −21.7 kcal/mol, which is greater
compared to those of 26 (−20.7 kcal/mol) and 5 (−20.4
kcal/mol) (Table 4) and in line with that of our potent Brd4
degrader MZ1 (−22.2 kcal/mol).5 VZ185 and its analogues 26
and 46 all showed low cell permeability in PAMPA assay,
suggesting that permeability is unlikely to be the main driver of
the enhanced degradation activity of VZ185 (Table S3). The
data together suggest that the thermodynamically more stable
ternary complex formed by VZ185 helps to drive its more potent
and rapid degradation activity, in spite of its low cell
permeability.
We next studied the functional mechanism of VZ185 by
conﬁrming proteasome and CRL2VHL involvement and
ubiquitination of BRD7 and BRD9 (Figure 10). Combined
treatment of the active degrader with the proteasome inhibitor
MG132 and the neddylation inhibitor MLN4924, which blocks
the activity of CRL2VHL,70 suppressed the degradation of BRD7
and BRD9, clearly indicating that the degradation is
proteasome- and CRL2VHL-dependent (Figure 10A). Moreover,
to investigate levels of target ubiquitination, NanoBRET
experiments were performed using the endogenously tagged
HiBiT-BRD7 and BRD9 as energy donors and a polyclonal-Ub
primary in conjunction with a ﬂuorescently labeled secondary
antibody as an energy acceptor (Figure 10B). Increases in BRET
can be observed over time after treatment with VZ185 for both
proteins, indicating PROTAC-induced target ubiquitination.
The observed signal was stronger for BRD9 as compared to
BRD7, consistent with the trends observed for VZ185 inducing
Table 4. Biophysical Comparison between BRD9 Degraders from Three Generations
ITCa FPb AlphaLISA
compd binary Kd (nM) ternary Kd (nM) α total ΔG (kcal/mol) binary Kd (nM) ternary Kd (nM) α max intensity
5 33 ± 2 73 ± 2 0.45 −20.4 24 ± 6 98 ± 2 0.24 1.0 × 106
26 87 ± 5 83 ± 2 1.05 −20.7 70 ± 14 60 ± 5 1.17 1.56 × 106
VZ185 26 ± 9 27 ± 3 0.96 −21.7 35 ± 5 35 ± 6 1.00 1.47 × 106
aAll ITC titrations were performed at 25 °C. Values reported are the mean ± SEM from at least two independent measurements (n ≥ 2). bKd
values are reported as the mean ± SEM of at least two individual experiments performed in triplicate.
Figure 10.Mechanistic characterization of VZ185 mode of action. (A) VZ185 activity is proteasome and CRL2VHL-dependent. RI-1 cells were treated
in two replicates with MG132, MLN4924, VH298, and cisVZ185 in the presence of absence of VZ185 (100 nM) at desired time points before
harvesting. (B) NanoBRET experiments in HEK293 cells to monitor ubiquitination of HiBiT endogenously tagged BRD9 (purple) or BRD7 (green)
using monoclonal-Ub primary and Alexa594 secondary antibodies at times indicated after treatment with 1 μMVZ185. Error bars expressed as SEM of
n = 3 experiments.
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preferential degradation of BRD9 compared to BRD7 (Figure
10B). Additionally, to conﬁrm the involvement of VHL in the
mechanism of action of VZ185, a competition assay with VHL
inhibitor VH298 (ref 62) was carried out. RI-1 cells were treated
with 100 μM VH298 30 min before adding VZ185 (100 nM),
and the cells were incubated for 4 h before cell lysis (Figure
10A). As anticipated, pretreatment with VHL inhibitor blocked
the degradation activity of VZ185. Moreover, since the trans
stereochemistry of the hydroxyl group of the hydroxyproline
moiety on VHL is essential for the binding to VHL,62,71 RI-1
cells were treated with cisVZ185 (100 nM) as inactive negative
control (synthesis detailed in the Supporting Information) for 4
h before harvesting. As expected, no degradation of BRD7 or
BDR9 was observed with cisVZ185 (Figure 10A).
We next assessed the impact of compound-induced BRD7/9
degradation on the viability of cancer cell lines. EOL-1 (acute
myeloid eosinophilic leukemia) and A-204 (malignant rhabdoid
tumor) cell lines were chosen because they are sensitive to
BRD9 inhibition/degradation18,56 and dependent on an active
BAF complex,72 respectively. Cellular ATP presence was
quantiﬁed as signal of metabolically active cells (Figure 11).
VZ185 was cytotoxic in both cell lines, with EC50 of 3 nM (EOL-
1) and 40 nM (A-402), and proved to be equipotent to CRBN-
based degrader 21 (dBRD9, EC50 of 5 and 90 nM, respectively)
(Figure 11). Diﬀerential cytotoxicity of BRD7/9 degradation by
VZ185 over and above BRD7/9 bromodomain inhibition was
clearly observed (EC50 of 90−340 nM and 370−3550 nM for
compounds 1a and 1b, respectively). The activity in A-204 cells
is of particular relevance as malignant rhabdoid tumors are rare,
chemoresistant cancers with poor survival rate (<25%) that are
distinctly characterized by biallelic inactivation of SMARCB1, a
core subunit of the BAF complex, suggesting speciﬁc
vulnerabilities.86
Finally, to assess the cellular selectivity of VZ185 for BRD7/9
degradation and identify potential degradation oﬀ-targets,
multiplexed isobaric tagging mass spectrometry proteomic
experiments were performed to monitor protein levels in a
quantitative and unbiased manner. RI-1 cells were treated in
triplicate with DMSO, 100 nM VZ185, or 100 nM cisVZ185 for
4 h. Among 6273 proteins quantiﬁed in this analysis, of those
that met the criteria for a statistically signiﬁcant change in
abundance (p-value y < 0.001; fold change {x < −20% U, x >
20%}, Figure 12 and Supporting Information Figures S11 and
S12), markedly selective degradation of BRD7 and BRD9 was
observed. As expected, BRD7/9 proteins were not depleted by
treatment with negative control cisVZ185 (Supporting In-
formation Figures S11 and S12). Protein levels of other
bromodomain-containing proteins or other BAF/PBAF sub-
units remained unaﬀected. To conﬁrm selectivity over key
potential oﬀ-target proteins within the bromodomain protein
family, live cell kinetic analyses of endogenously tagged BRD2/
3/4 and SMARCA4 proteins expressing LgBiT were performed
(Supporting Information Figure S13). These results together
with the proteomic data conﬁrmed VZ185 as an eﬀective and
highly selective degrader of BRD7/9 proteins in cells. In vitro
PK data further showed high stabilities of VZ185 in both plasma
and microsomes from both human and mouse species, as well as
high aqueous kinetic solubility (up to ∼100 μM, Table S3).
Together, the data qualify VZ185 as a novel high-quality
degrader probe for cellular and potentially in vivo investigations.
Figure 11. Eﬀect of BRD7/9 degradation on viability of BRD9-sensitive cancer cell lines. Cell proliferation activity assessed in EOL-1 (A) and A-204
(B) cell lines after treatment with 1a, 1b, VZ185, 7, 21 (dBRD9), and doxorubicin for 7 days.
Figure 12. Impact of VZ185 on the cellular proteome after treatment of
RI-1 cells with 100 nM compound for 4 h before harvesting. Data are
plotted as fold change (%) versus−log10 of p-value (t test) for a total of
6273 proteins, expressed as the mean of the replicates. For
quantiﬁcation, see Experimental Section.
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■ CONCLUSION
We describe the development of a new series of PROTACs
against BRD9, a target thought as not degradable through
recruitment of the E3 ligase VHL. In spite of starting from
unimpressive degradation proﬁles of initial compounds, VHL-
based degraders could be optimized by systematically varying
the conjugation patterns and monitoring cellular degradation
activities and formation of ternary complexes. Throughout the
campaign, we revealed important structure−activity relation-
ships that proved invaluable to guide the optimization search
space and led to signiﬁcant improvements in degradation
activities. We thoroughly characterize VZ185 as a highly
selective, potent, and rapid dual degrader with a slight preference
for BRD9 over BRD7. Our ﬁndings thus qualify VZ185 as a new
high-quality chemical probe that will be valuable to explore the
biology and therapeutic potential of degrading these two
proteins.
Biophysical and mechanistic studies suggest that increased
ternary complex stability correlates with improved degradation
proﬁles. The absence of positive cooperativity in VZ185 allows
much scope for optimizing the thermodynamics of ternary
complex formation, which in turn should warrant enhanced
degradation activities of future compounds.5,11,32 Further
investigation of the contributing factors of single-target
selectivity would be important and could also allow rational
design of single-target selective degraders, for example, for
BRD7 over BRD9. More generally, this successful campaign
exempliﬁes a broadly applicable approach to arrive at degraders
that are eﬀective for any target−ligase pairs, even those that
might have been considered unproductive based on negative
studies with initial compounds. It is thus tempting to speculate
that there may not exist a preferred E3 ligase for “PROTACing”
a given target protein. Any E3 ligase might, in principle, be
hijacked for productive target ubiquitination and degradation,
provided the combinatorial chemical space is adequately
explored.
■ EXPERIMENTAL SECTION
Chemistry. Synthesis. Chemicals, commercially available, were
purchased from Apollo Scientiﬁc, Sigma-Aldrich, Fluorochem, or
Manchester Organics and used without any further puriﬁcation. All
reactions were carried out using anhydrous solvents. Analytical thin-
layer chromatography (TLC) was performed on precoated TLC plates
(layer 0.20 mm silica gel 60 with ﬂuorescent indicator (UV 254:
Merck)). The TLC plates were air-dried and revealed under UV lamp
(254/365 nm). Flash column chromatography was performed using
prepacked silica gel cartridges (230−400 mesh, 40−63 mm; SiliCycle)
using a Teledyne ISCO Combiﬂash Companion or Combiﬂash
Retrieve using the solvent mixtures stated for each synthesis as mobile
phase. Liquid chromatography−mass spectrometry (LC−MS) analyses
were performed with either an Agilent HPLC 1100 series connected to
a Bruker Daltonics MicroTOF or an Agilent Technologies 1200 series
HPLC connected to an Agilent Technologies 6130 quadrupole
spectrometer or a Waters 2795 connected to a Waters ZQ Micromass
spectrometer; all instruments were connected to a diode array detector.
All of the ﬁnal compounds used in all of the experiments were evaluated
after preparative LC−MS separations with a Waters X-bridge C18
column (50 mm × 2.1 mm × 3.5 mm particle size); ﬂow rate, 0.5 mL/
min with a mobile phase of water/MeCN + 0.1% NH4OH or water/
MeCN + 0.1% CHOOH; 95/5 water/MeCN was initially held for 0.5
min followed by a linear gradient from 95/5 to 5/95 water/MeCN over
3.5 min which was then held for 2 min. The purity of all the compounds
was evaluated using the analytical LC−MS system described before,
and purity was >95%. 1HNMR and 13CNMR spectra were recorded on
a Bruker Avance II 500 spectrometer (1H at 500.1 MHz, 13C at 125.8
MHz) or on a Bruker DPX-400 spectrometer (1H at 400.1 MHz, 13C at
101 MHz). Chemical shifts (δ) are expressed in ppm reported using
residual solvent as the internal reference in all cases. Signal splitting
patterns are described as singlet (s), doublet (d), triplet (t), multiplet
(m), or a combination thereof. Coupling constants (J) are quoted to the
nearest 0.1 Hz.
General Method A. To a mixture of aryl bromide (1 equiv) in
dioxane (0.2M), Pd(dppf)Cl2 (0.1 equiv), bis(pinacolato)diboron (1.2
equiv), and KOAc (3 equiv) were added. Themixture was heated under
microwave conditions at 140 °C for 40 min. Then aryl iodide 14 (1
equiv) and a degassed solution of K2CO3 2 M (2 equiv) were added.
The reaction mixture was heated in microwave at 120 °C for 30 min.
The resulting mixture was ﬁltered through Celite and washed several
times with DCM. The organic phase was washed with H2O and brine,
dried over MgSO4, ﬁltered, and evaporated in vacuum. The crude was
puriﬁed by ﬂash column chromatography using a gradient from 0% to
20% of MeOH in DCM to obtain the desired compound. Then the
intermediate was taken up in a mixture 1:1 HCl 4 N in dioxane/DCM
and stirred at rt for 3 h. The solvents were evaporated to dryness to
obtain the desired compound as hydrochloride salt.
General Method B. To a solution of acid (1 equiv) in DMF (0.2
M), HATU (1 equiv), HOAt (1 equiv), amine (1 equiv), and DIPEA (5
equiv) were added. The reaction mixture was stirred at rt for 2 h. The
solvent was evaporated under reduced pressure to give the
corresponding crude, which was chromatographically puriﬁed to yield
the ﬁnal compound.
General Method C. A mixture of aldehyde (1 equiv), amine (HCl
salt, 1.1 equiv), and TEA (1.1 equiv) in DMF (0.2 M) was stirred at rt.
After 15 min, NaBH(OAc)3 (1.5 equiv) was added, and the reaction
was stirred overnight at rt under nitrogen. The solvent was evaporated
under reduced pressure to give the corresponding crude, which was
puriﬁed accordingly to yield the desired compound.
General Method D. To a stirred solution of oxalyl chloride (1.5
equiv) in DCM (0.3 M), DMSO (2 equiv) was added dropwise at −78
°C. After 10 min at −78 °C, the alcohol starting material (1 equiv) in
DCM (0.3 M) was added. The reaction was stirred at −78 °C for 1 h,
TEA (10 equiv) was added dropwise, and temperature was increased to
rt. After 1 h, the reaction mixture was diluted with DCM, washed with a
saturated solution of ammonium chloride. The organic phases were
combined, washed with brine, dried over MgSO4, ﬁltered, and
evaporated to dryness. Then the crude was dissolved in DMF (0.05
M); 1c (1 equiv) and TEA (1.1 equiv) were added. After 15 min,
NaBH(OAc)3 was added and the reactionmixture was stirred overnight
at rt under nitrogen. The solvent was evaporated under reduced
pressure to give the corresponding crude, which was puriﬁed by
preparative HPLC to yield the desired compound.
General Method E.To a solution of the alcohol starting material (1
equiv) and trimethylamine (1.5 equiv) in DCM (0.2 M),
methansulfonyl chloride (1.2 equiv) was added at 0 °C. The reaction
mixture was stirred at 0 °C for 3 h. The reaction was quenched with a
saturated solution of ammonium chloride and extracted with DCM.
The organic phases were combined, dried over MgSO4, ﬁltered, and
evaporated to dryness. The crude (1.5 equiv) was suspended in DMF
(0.2 M), and 2b−d inhibitor derivative (1 equiv) and K2CO3 (3 equiv)
were added. The mixture was heated overnight at 70 °C. The reaction
mixture was diluted with water and extracted with DCM. The organic
phases were combined, dried over MgSO4, ﬁltered, and evaporated to
dryness. The crude was puriﬁed by ﬂash column chromatography using
a gradient from 0% to 20% of MeOH in DCM to yield the desired
compound.
General Method F. A 1 M aqueous solution of HCl (1 mL) was
added to the VHL-acetal linker (0.06 mmol) in THF (1 mL). The
reaction mixture was heated at 50 °C for 2 h. The solvent was
evaporated under reduced pressure, and the product was extracted with
DCM/MeOH (9:1). The organic phases were combined, dried over
MgSO4, ﬁltered, and evaporated to dryness. The crude was used
directly without any further puriﬁcation.
General method G. Aldehyde (1 equiv) was taken up in t-BuOH
and water (4:1) (0.3 M). Then 2-methyl-2-butene 2 M in THF (4
equiv) was added, followed by sodium phosphate dibasic (1 equiv) and
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sodium chlorite (2 equiv). The reaction mixture was stirred at rt for 4 h.
A 1 M aqueous solution of HCl was added. The product was extracted
with DCM. The organic phases were combined, dried over MgSO4,
ﬁltered, and evaporated to dryness. The crude was used directly without
any further puriﬁcation.
4-(3,5-Dimethoxy-4-(piperazin-1-ylmethyl)phenyl)-2-meth-
yl-2,7-naphthyridin-1(2H)-one (1c). Following general method A,
compound 1c was obtained from compound 12 and 14 as brown
powder. Yield: 50 mg, 55%. 1H NMR (400 MHz, MeOD) δ: 9.67 (s,
1H), 8.76 (d, J = 6.9 Hz, 1H), 8.27 (s, 1H), 8.21 (d, J = 6.9 Hz, 1H),
6.95 (s, 2H), 4.62 (s, 2H), 4.03 (s, 6H), 3.81 (s, 3H), 3.73 (s, 8H). 13C
NMR (101 MHz, CDCl3) δ: 161.5, 161.4, 148.6, 146.3, 145.5, 141.9,
139.7, 122.9, 117.9, 107.1, 105.8, 57.2, 50.8, 49.7, 41.9, 37.9. MS m/z
calcd for C22H26N4O3 394.2, found 395.3 [M + H
+].
(2S,4R)-1-((S)-2-(2-(2-(2-(4-(2,6-Dimethoxy-4-(2-methyl-1-
oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)-
ethoxy)ethoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-
N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
(5). Following general method B, compound 5 was obtained from 19
and 2a (synthesized accordingly to literature61). The crude was puriﬁed
by HPLC using a gradient of 5% to 95% v/v acetonitrile in 0.1%
aqueous solution of formic acid to obtain 5 as white powder. Yield: 6.3
mg, 44%. 1H NMR (400 MHz, MeOD) δ: 9.44 (s, 1H), 8.80 (s, 1H),
8.59 (d, J = 5.5Hz, 1H), 7.66 (s, 1H), 7.54 (d, J = 5.9Hz, 1H), 7.37 (q, J
= 7.8 Hz, 4H), 6.73 (s, 2H), 4.66 (s, 1H), 4.52−4.26 (m, 4H), 4.05−
3.95 (m, 4H), 3.86−3.72 (m, 8H), 3.69−3.59 (m, 9H), 2.96−2.73 (m,
10H), 2.40 (s, 3H), 2.21−2.14 (m, 1H), 2.06−1.97 (m, 1H), 0.99 (s,
9H). 13CNMR (101MHz,MeOD) δ: 174.3, 172.0, 171.7, 163.0, 161.0,
152.8, 151.7, 151.2, 149.1, 143.5, 140.3, 139.0, 133.3, 131.6, 130.5,
130.4, 129.5, 129.0, 121.7, 119.2, 119.0, 106.6, 72.2, 71.3, 71.1, 71.0,
69.1, 60.9, 58.2, 58.1, 57.9, 56.6, 52.8, 52.4, 43.7, 39.0, 37.4, 37.2, 27.0,
15.8. HRMSm/z calcd for C50H64N8O9S 952.45, found 953.4728 [M +
H+].
(2S,4R)-1-((S)-2-(tert-Butyl)-17-(4-(2,6-dimethoxy-4-(2-
methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)-
piperazin-1-yl)-4-oxo-6,9,12,15-tetraoxa-3-azaheptadecano-
yl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-
2-carboxamide (6). Following general method B, compound 6 was
obtained from 20 and 2a (synthesized accordingly to literature61). The
crude was puriﬁed by HPLC using a gradient of 5% to 95% v/v
acetonitrile in 0.1% aqueous solution of formic acid to obtain 6 as white
powder. Yield: 4.9 mg, 30%. 1H NMR (400 MHz, MeOD) δ: 9.44 (s,
1H), 8.81 (s, 1H), 8.60 (d, J = 5.6 Hz, 1H), 7.67 (s, 1H), 7.54 (d, J = 5.6
Hz, 1H), 7.37 (q, J = 9.0 Hz, 4H), 6.73 (s, 2H), 4.63 (s, 1H), 4.53−4.26
(m, 4H), 4.02−3.94 (m, 4H), 3.84−3.72 (m, 8H), 3.66−3.50 (m,
17H), 2.89−2.67 (m, 10H), 2.41 (s, 3H), 2.20−2.14 (m, 1H), 2.06−
1.97 (m, 1H), 0.98 (s, 9H). 13C NMR (101 MHz, MeOD) δ: 174.4,
172.0, 171.7, 163.0, 161.0, 152.9, 151.7, 151.2, 149.1, 143.5, 140.3,
139.0, 138.6, 133.4, 131.5, 130.5, 130.4, 129.5, 129.0, 121.7, 119.2,
119.1, 106.6, 72.3, 71.7, 71.6, 71.5, 71.4, 71.1, 71.0, 68.9, 60.9, 58.2,
58.0, 56.6, 52.8, 43.7, 39.0, 37.4, 37.1, 27.0, 15.9. HRMS m/z calcd for
C54H72N8O11S 1040.50, found 1041.5287 [M + H
+].
2-(2-(2-(4-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-
2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)ethoxy)ethoxy)-
N-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)-
amino)ethyl)acetamide (7). Following general method B, com-
pound 7 was obtained from compound 19 and 3a (synthesized
accordingly to literature73). The crude was puriﬁed by HPLC using a
gradient of 5% to 95% v/v acetonitrile in 0.1% aqueous solution of
formic acid to obtain compound 7 as yellow powder. Yield: 5.6 mg,
33%. 1H NMR (400MHz, MeOD) δ: 9.54 (d, J = 0.8 Hz, 1H), 8.70 (d,
J = 6.0 Hz, 1H), 8.11 (s, 1NH), 7.84 (s, 1H), 7.73 (dd, J = 0.6, 6.0 Hz,
1H), 7.55−7.49 (m, 1H), 7.10−7.03 (m, 2H), 6.87 (s, 2H), 5.08 (dd, J
= 5.5, 12.7 Hz, 1H), 4.38 (s, 2H), 4.05 (s, 2H), 3.96 (s, 6H), 3.77−3.67
(m, 9H), 3.51−3.46 (m, 4H), 3.39 (s, 4H), 3.20 (s, 4H), 3.01 (t, J = 4.8
Hz, 2H), 2.94−2.67 (m, 4H). 13C NMR (101 MHz, MeOD) δ: 174.6,
173.4, 171.6, 170.6, 169.1, 162.7, 161.1, 150.9, 149.8, 147.9, 144.0,
140.1, 137.2, 133.9, 121.8, 119.6, 118.5, 117.9, 112.2, 111.4, 106.7, 71.7,
71.3, 71.0, 67.7, 57.5, 56.8, 51.8, 51.1, 50.2, 50.0, 42.6, 39.4, 37.5, 32.2,
23.8. HRMSm/z calcd for C43H50N8O10 838.36, found 839.3796 [M +
H+].
14-(4-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-
naphthyridin-4-yl)benzyl)piperazin-1-yl)-N-(2-((2-(2,6-dioxo-
piperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethyl)-
3,6,9,12-tetraoxatetradecanamide (8). Following general method
B, compound 8 was obtained from compound 20 and 3a (synthesized
accordingly to literature73). The crude was puriﬁed by HPLC using a
gradient of 5% to 95% v/v acetonitrile in 0.1% aqueous solution of
formic acid to obtain compound 8 as yellow powder. Yield: 10 mg, 54%.
1H NMR (400 MHz, MeOD) δ: 9.53 (s, 1H), 8.70 (d, J = 5.7 Hz, 1H),
8.15 (s, 1NH), 7.77 (s, 1H), 7.64 (d, J = 5.7 Hz, 1H), 7.59−7.53 (m,
1H), 7.17−7.13 (m, 1H), 7.08−7.04 (m, 1H), 6.86 (s, 2H), 5.07 (dd, J
= 5.5, 12.5 Hz, 1H), 4.29 (s, 2H), 4.01 (s, 2H), 3.96 (s, 6H), 3.72−3.63
(m, 17H), 3.54 (s, 4H), 3.25 (s, 4H), 3.02 (s, 4H), 2.94−2.67 (m, 6H).
13C NMR (101 MHz, MeOD) δ: 174.6, 173.5, 171.5, 170.6, 169.2,
163.0, 161.0, 151.7, 151.2, 148.0, 143.4, 139.8, 139.2, 137.3, 133.9,
121.7, 119.1, 118.7, 118.1, 112.1, 111.4, 108.1, 106.7, 72.0, 71.4, 71.1,
68.5, 57.6, 56.8, 52.4, 51.6, 50.2, 49.9, 42.5, 39.4, 37.5, 32.2, 23.8.
HRMS m/z calcd for C47H58N8O12 926.42, found 927.4396 [M + H
+].
N-(4-(N-(3-Chloro-1H-indol-7-yl)sulfamoyl)benzyl)-2-(2-(2-
(4-(2,6-dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naph-
thyridin-4-yl)benzyl)piperazin-1-yl)ethoxy)ethoxy)acetamide
(9). Following general method B, compound 9 was obtained from
compound 19 and 4a (synthesis detailed in the Supporting
Information). The crude was puriﬁed by HPLC using a gradient of
5% to 95% v/v acetonitrile in 0.1% aqueous solution of formic acid to
obtain compound 9 as white powder. Yield: 10.8 mg, 34%. 1H NMR
(400 MHz, MeOD) δ: 9.54 (s, 1H), 8.69 (d, J = 5.8 Hz, 1H), 8.27 (s,
1NH), 7.75 (s, 1H), 7.68−7.62 (m, 3H), 7.39 (d, J = 8.3 Hz, 2H), 7.33
(dd, J = 0.9, 8.1 Hz, 1H), 7.26 (s, 1H), 6.91 (t, J = 7.8 Hz, 1H), 6.85 (s,
2H), 6.70 (d, J = 7.7 Hz, 1H), 4.49 (s, 2H), 4.28 (s, 2H), 4.11 (s, 2H),
3.94 (s, 6H), 3.76−3.66 (m, 7H), 3.63 (t, J = 5.3 Hz, 2H), 3.22 (s, 4H),
2.88 (s, 4H), 2.73 (t, J = 5.1 Hz, 2H). 13C NMR (101 MHz, MeOD) δ:
173.0, 166.4, 163.0, 161.0, 151.7, 151.2, 145.5, 143.3, 140.0, 139.4,
139.1, 132.0, 128.8, 128.7, 128.2, 123.4, 122.7, 121.6, 120.9, 119.4,
119.1, 118.8, 117.0, 107.5, 106.7, 106.2, 71.9, 71.4, 71.3, 68.7, 57.6,
56.8, 52.5, 51.3, 49.9, 43.0, 37.5. HRMS m/z calcd for C43H48ClN7O8S
857.30, found 858.3111 [M + H+].
N-(4-(N-(3-Chloro-1H-indol-7-yl)sulfamoyl)benzyl)-14-(4-
(2,6-dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyri-
din-4-yl)benzyl)piperazin-1-yl)-3,6,9,12-tetraoxatetra-
decanamide (10). Following general method B, compound 10 was
obtained from compound 20 and 4a (synthesis detailed in the
Supporting Information). The crude was puriﬁed by HPLC using a
gradient of 5% to 95% v/v acetonitrile in 0.1% aqueous solution of
formic acid to obtain compound 10 as white powder. Yield: 11.1 mg,
37%. 1H NMR (400 MHz, MeOD) δ: 9.54 (d, J = 0.6 Hz, 1H), 8.69 (d,
J = 5.7 Hz, 1H), 8.30 (s, 1NH), 7.75 (s, 1H), 7.68−7.62 (m, 3H), 7.41
(d, J = 8.2Hz, 2H), 7.34 (dd, J = 0.8, 8.1 Hz, 1H), 7.27 (s, 1H), 6.92 (t, J
= 7.8 Hz, 1H), 6.84 (s, 2H), 6.72 (dd, J = 0.9, 7.5 Hz, 1H), 4.50 (s, 2H),
4.26 (s, 2H), 4.09 (s, 2H), 3.94 (s, 6H), 3.73−3.67 (m, 7H), 3.65−3.59
(m, 4H), 3.58−3.53 (m, 6H), 3.22 (s, 4H), 2.96 (s, 4H), 2.82 (t, J = 5.3
Hz, 2H). 13C NMR (101 MHz, MeOD) δ: 173.1, 166.7, 163.1, 161.0,
151.7, 151.2, 145.5, 143.4, 139.7, 139.2, 139.0, 131.9, 128.9, 128.6,
128.2, 123.4, 122.7, 121.6, 121.0, 119.3, 119.2, 118.9, 117.0, 108.0,
106.7, 106.2, 72.0, 71.3, 71.3, 71.2, 68.3, 57.5, 56.8, 52.3, 51.5, 49.9,
42.9, 37.6. HRMS m/z calcd for C47H56ClN7O10S 945.35, found
946.3676 [M + H+].
tert-Butyl 4-(4-Bromo-2,6-dimethoxybenzyl)piperazine-1-
carboxylate (12). Following general method C, compound 12 was
obtained from 4-bromo-2,6-dimethoxybenzaldehyde (11) and boc-
piperazine (both commercially available). The reaction was quenched
with saturated solution of NaHCO3, extracted with DCM, washed with
water and brine. The organic phases were combined, dried overMgSO4,
ﬁltered, and evaporated to dryness to give the desired compound
without any further puriﬁcation as sticky oil. Yield: 495 mg, 97%. 1H
NMR (500 MHz, CDCl3) δ: 6.69 (s, 2H), 3.78 (s, 6H), 3.62 (s, 2H),
3.38 (t, J = 5.0 Hz, 4H), 2.41 (t, J = 4.4 Hz, 4H), 1.43 (s, 9H). 13CNMR
(125 MHz, CDCl3) δ: 159.9, 154.7, 122.8, 107.7, 79.8, 56.1, 51.8, 48.5,
31.0, 28.5. MS m/z calcd for C18H27BrN2O4 414.12, found 415.2 [M +
H+].
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4-Iodo-2-methyl-2,7-naphthyridin-1(2H)-one (14). A mixture
of 4-iodo-2,7-naphthyridin-1(2H)-one 13 (synthesized accordingly to
literature74) (1 equiv) and NaH (2 equiv) was stirred 30 min at 0 °C in
DMF (0.2 M). Then CH3I (1.6 equiv) was added and the reaction
mixture was stirred at 0 °C for 5 h. Water was added, and the precipitate
formed was ﬁltered and dried in vacuum. Yield: 300 mg, 95%. 1H NMR
(400 MHz, DMSO) δ: 9.27 (s, 1H), 8.82 (d, J = 5.6 Hz, 1H), 8.26 (s,
1H), 7.47 (d, J = 5.5 Hz, 1H), 3.52 (s,3H). 13C NMR (101 MHz,
DMSO) δ: 160.3, 152.0, 150.3, 144.8, 143.0, 122.4, 120.7, 67.9, 36.2.
MS m/z calcd for C9H7IN2O 285.96, found 287.1 [M + H
+].
tert-Butyl 2-(2-(2-(4-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-
dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)ethoxy)-
ethoxy)acetate (17). Following general methodD, compound 17was
obtained from tert-butyl 2-(2-(2-hydroxyethoxy)ethoxy)acetate 15 and
1c after puriﬁcation by HPLC using a gradient of 5% to 95% v/v
acetonitrile in 0.1% aqueous solution of ammonia as white powder.
Yield: 8.8 mg, 32%. 1HNMR (500MHz, CDCl3) δ: 9.69 (d, J = 0.8 Hz,
1H), 8.70 (d, J = 5.7 Hz, 1H), 7.43 (dd, J = 0.8, 5.6 Hz, 1H), 7.26 (s,
1H), 6.52 (s, 2H), 4.00 (s, 2H), 3.81 (s, 6H), 3.70−3.60 (m, 11H),
2.65−2.56 (m, 10H), 1.46 (s, 9H). 13C NMR (125 MHz, CDCl3) δ:
170.0, 161.8, 160.0, 152.0, 151.3, 142.1, 136.1, 135.5, 120.8, 118.4,
117.8, 113.9, 105.7, 81.9, 71.0, 70.7, 69.3, 58.1, 56.2, 53.7, 52.6, 48.9,
37.4, 28.4. MS m/z calcd for C32H44N4O7 596.32, found 597.34 [M +
H+].
tert-Butyl 14-(4-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-di-
hydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)-3,6,9,12-
tetraoxatetradecanoate (18). Following general method D,
compound 18 was obtained from tert-butyl 14-hydroxy-3,6,9,12-
tetraoxatetradecanoate 16 and 1c after puriﬁcation by HPLC using a
gradient of 5% to 95% v/v acetonitrile in 0.1% aqueous solution of
ammonia as white powder. Yield: 10.7 mg, 34%. 1H NMR (500 MHz,
CDCl3) δ: 9.69 (d, J = 0.8 Hz, 1H), 8.70 (d, J = 5.6 Hz, 1H), 7.43 (d, J =
5.6 Hz, 1H), 7.26 (s, 1H), 6.52 (s, 2H), 4.00 (s, 2H), 3.81 (s, 6H),
3.73−3.57 (m, 19H), 2.67−2.55 (m, 10H), 1.46 (s, 9H). 13C NMR
(125 MHz, CDCl3) δ: 170.0, 161.8, 160.0, 152.0, 151.3, 142.1, 136.2,
120.8, 118.4, 117.8, 105.7, 81.9, 71.1, 70.9, 70.7, 69.4, 69.2, 58.0, 56.3,
53.8, 52.4, 48.9, 37.5, 28.5. MS m/z calcd for C36H52N4O9 684.37,
found 685.39 [M + H+].
2-(2-(2-(4-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-
2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)ethoxy)ethoxy)-
acetic Acid (19). A mixture of compound 17 (0.015 mmol), TFA (0.5
mL), and DCM (0.5 mL) was stirred at rt for 3 h. Then the solvent was
evaporated; the crude was dried under high pressure overnight and used
directly in the next step without any further puriﬁcation. Quantitative
yield. MS m/z calcd for C28H36N4O7 540.26, found 541.4 [M + H
+].
17-(4-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-
naphthyridin-4-yl)benzyl)piperazin-1-yl)-3,6,9,12,15-
pentaoxaheptadecanoic Acid (20). A mixture of compound 18
(0.034mmol), TFA (0.5mL), andDCM (0.5mL) was stirred at rt for 3
h. Then the solvent was evaporated; the crude was dried under high
pressure overnight and used directly without any further puriﬁcation.
Quantitative yield. MS m/z calcd for C34H48N4O10 672.34, found
673.36 [M + H+].
(2R,4S)-1-((R)-2-(2-(2-((5-(4-(2,6-Dimethoxy-4-(2-methyl-1-
oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)-
pentyl)oxy)ethoxy)acetamido)-3,3-dimethylbutanoyl)-4-hy-
droxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-car-
boxamide (23). A mixture of 35 (1 equiv), osmium tetroxide 4% in
H2O (0.2 equiv), sodium periodate (4 equiv), pyridine (2 equiv) in
dioxane/H2O (3:1) was stirred at rt for 48 h. Then H2O was added to
the reaction and the product was extracted with DCM. The organic
phases were combined, dried over MgSO4, ﬁltered, and evaporated to
dryness. The crude was dissolved in DCE, and a mixture of 1c (1 equiv)
and TEA (1.1 equiv) in DCE (0.02 M) was added. After 15 min,
NaBH(OAc)3 was added and the reaction mixture was stirred at rt for 4
h under nitrogen. The solvent was evaporated under reduced pressure
to give the corresponding crude, which was puriﬁed by HPLC using a
gradient of 5% to 95% v/v acetonitrile in 0.1% aqueous solution of
ammonia. Compound 23 was obtained as a white powder. Yield: 6.9
mg, 54%. 1H NMR (400 MHz, CDCl3) δ: 9.68 (s, 1H), 8.69 (d, J = 5.6
Hz, 1H), 8.66 (s, 1H), 7.41 (dd, J = 0.6, 5.6 Hz, 1H), 7.37−7.32 (m,
4H), 7.27 (s, 1H), 6.53 (s, 2H), 4.72 (t, J = 8.0 Hz, 1H), 4.59−4.49 (m,
3H), 4.35−4.29 (m, 1H), 4.07−3.95 (m, 3H), 3.85−3.80 (m, 8H),
3.67−3.55 (m, 8H), 3.43 (t, J = 6.4 Hz, 2H), 2.74−2.37 (m, 14H),
2.15−2.09 (m, 1H), 1.60−1.47 (m, 4H), 1.36−1.27 (m, 2H), 0.94 (s,
9H). 13CNMR (101MHz, CDCl3) δ: 171.5, 170.9, 170.5, 168.6, 161.6,
159.8, 151.8, 151.1, 150.4, 148.6, 141.9, 138.3, 136.0, 131.7, 131.1,
129.6, 128.3, 120.6, 118.1, 117.6, 105.5, 71.4, 71.3, 70.6, 70.1, 58.6,
58.2, 57.2, 56.9, 56.1, 52.5, 51.7, 48.6, 43.4, 37.3, 36.1, 35.2, 29.4, 26.6,
26.0, 24.2, 16.2. HRMS m/z calcd for C53H70N8O9S 994.50, found
995.5178 [M + H+].
(2S,4R)-N-(2-(2-(2-(2-(4-(2,6-Dimethoxy-4-(2-methyl-1-oxo-
1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)-
ethoxy)ethoxy)ethoxy)-4-(4-methylthiazol-5-yl)benzyl)-1-((S)-
2-(1-ﬂuorocyclopropane-1-carboxamido)-3,3-dimethylbuta-
noyl)-4-hydroxypyrrolidine-2-carboxamide (26).Amixture of 40
(1 equiv), osmium tetroxide 4% in H2O (0.2 equiv), sodium periodate
(4 equiv), pyridine (2 equiv) in dioxane/H2O (3:1) was stirred at rt for
48 h. Then H2O was added to the reaction and the product was
extracted with DCM. The organic phases were combined, dried over
MgSO4, ﬁltered, and evaporated to dryness. Then, following general
method A, compound 26 was synthesized from the aldehyde derivative
and 1c. The solvent was removed in vacuum to give the corresponding
crude, which was puriﬁed by HPLC using a gradient of 5% to 95% v/v
acetonitrile in 0.1% aqueous solution of formic acid to yield compound
26 as white powder. Yield: 7 mg, 45%. 1H NMR (400 MHz, MeOD) δ:
9.54 (s, 1H), 8.90 (s, 1H), 8.70 (d, J = 5.8 Hz, 1H), 8.58 (s, 1NH), 7.75
(s, 1H), 7.63 (dd, J = 0.6, 5.7 Hz, 1H), 7.51 (d, J = 7.8 Hz, 1H), 7.10−
7.04 (m, 2H), 6.79 (s, 2H), 4.78 (s, 1H), 4.66 (t, J = 8.4 Hz, 1H), 4.55−
4.42 (m, 3H), 4.32−4.23 (m, 2H), 3.97−3.77 (m, 14H), 3.73−3.66 (m,
7H), 2.85−2.68 (m, 10H), 2.52 (s, 3H), 2.30−2.24 (m, 1H), 2.16−2.09
(m, 1H), 1.46−1.27 (m, 4H), 1.07 (s, 9H). 13C NMR (101 MHz,
MeOD) δ: 174.2, 171.7, 171.5, 171.3, 170.2, 163.0, 161.0, 158.0, 152.8,
151.7, 151.2, 149.1, 143.6, 138.9, 138.1, 133.5, 132.9, 130.0, 128.4,
122.9, 121.7, 119.2, 113.8, 106.5, 80.3, 78.0, 71.8, 71.4, 71.0, 70.8, 69.4,
69.3, 60.8, 58.7, 58.3, 58.2, 56.5, 53.3, 53.0, 39.5, 39.0, 37.4, 37.3, 26.9,
16.0, 14.1, 14.0, 13.9. MSm/z calcd for C54H69FN8O10S 1040.48, found
1041.4430 [M + H+].
(2S,4R)-1-((S)-2-(1-Cyanocyclopropane-1-carboxamido)-3,3-
dimethylbutanoyl)-N-(2-(2-(2-(2-(4-(2,6-dimethoxy-4-(2-meth-
yl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-
1-yl)ethoxy)ethoxy)ethoxy)-4-(4-methylthiazol-5-yl)benzyl)-
4-hydroxypyrrolidine-2-carboxamide (27). A mixture of 42 (1
equiv), osmium tetroxide 4% in H2O (0.2 equiv), sodium periodate (4
equiv), pyridine (2 equiv) in dioxane/H2O (3:1) was stirred at rt for 48
h. Then H2O was added to the reaction and the product was extracted
with DCM. The organic phases were combined, dried over MgSO4,
ﬁltered, and evaporated to dryness. Then, following general method A,
from the aldehyde derivative and 1c compound 27 was obtained after
puriﬁcation by HPLC using a gradient of 5% to 95% v/v acetonitrile in
0.1% aqueous solution of formic acid as white powder. Yield: 11 mg,
44%. 1H NMR (400 MHz, MeOD) δ: 9.55 (s, 1H), 8.90 (s, 1H), 8.69
(d, J = 5.8 Hz, 1H), 8.58 (s, 1NH), 7.75 (s, 1H), 7.63 (d, J = 5.6 Hz,
1H), 7.50 (d, J = 7.7 Hz, 1H), 7.10−7.03 (m, 2H), 6.79 (s, 2H), 4.71−
4.63 (m, 2H), 4.56−4.42 (m, 3H), 4.33−4.23 (m, 2H), 3.98−3.66 (m,
21H), 2.86−2.69 (m, 10H), 2.52 (s, 3H), 2.30−2.23 (m, 1H), 2.16−
2.08 (m, 1H), 1.70−1.55 (m, 4H), 1.06 (s, 9H). 13C NMR (101 MHz,
MeOD) δ: 174.1, 171.5, 170.1, 167.1, 163.0, 161.0, 158.1, 152.8, 151.7,
151.2, 149.1, 143.5, 138.9, 138.1, 133.4, 132.9, 130.1, 128.4, 122.8,
121.7, 120.8, 119.2, 119.2, 113.8, 106.5, 71.8, 71.4, 71.0, 70.8, 69.4,
69.2, 60.8, 59.5, 58.3, 58.1, 56.5, 53.2, 53.0, 39.5, 38.9, 37.7, 37.4, 26.8,
18.1, 18.0, 16.0, 14.8. HRMS m/z calcd for C55H69N9O10S 1047.49,
found 1048.4493 [M + H+].
(2S,4R)-1-((S)-2-Acetamido-3,3-dimethylbutanoyl)-N-(2-(2-
(2-(2-(4-(2,6-dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-
naphthyridin-4-yl)benzyl)piperazin-1-yl)ethoxy)ethoxy)-
ethoxy)-4-(4-methylthiazol-5-yl)benzyl)-4-hydroxy-
pyrrolidine-2-carboxamide (28). A mixture of 44 (1 equiv),
osmium tetroxide 4% in H2O (0.2 equiv), sodium periodate (4
equiv), pyridine (2 equiv) in dioxane/H2O (3:1) was stirred at rt for 48
h. Then H2O was added to the reaction and the product was extracted
with DCM. The organic phases were combined, dried over MgSO4,
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ﬁltered, and evaporated to dryness. Then, following general method A,
from the aldehyde derivative and 1c compound 28 was obtained after
puriﬁcation by HPLC using a gradient of 5% to 95% v/v acetonitrile in
0.1% aqueous solution of formic acid as white powder. Yield: 3.3 mg,
17%. 1H NMR (400 MHz, MeOD) δ: 9.55 (d, J = 0.7 Hz, 1H), 8.90 (s,
1H), 8.70 (d, J = 5.9 Hz, 1H), 7.76 (s, 1H), 7.64 (dd, J = 0.7, 5.9 Hz,
1H), 7.52 (d, J = 7.7 Hz, 1H), 7.09 (d, J = 1.5 Hz, 1H), 7.03 (dd, J = 1.7,
7.7 Hz, 1H), 6.79 (s, 2H), 4.65−4.60 (m, 2H), 4.54−4.42 (m, 3H),
4.28−4.25 (m, 2H), 3.96−3.65 (m, 21H), 2.86−2.67 (m, 10H), 2.52 (s,
3H), 2.27−2.21 (m, 1H), 2.15−2.08 (m, 1H), 2.04 (s, 3H), 1.05 (s,
9H). 13CNMR (101MHz,MeOD) δ: 174.4, 173.1, 172.3, 163.1, 161.0,
158.0, 152.8, 151.7, 151.2, 149.1, 143.6, 138.9, 133.5, 132.9, 130.0,
128.4, 122.8, 121.7, 119.2, 113.7, 106.5, 71.8, 71.4, 71.1, 70.8, 69.4,
69.2, 60.7, 59.2, 58.2, 58.0, 56.5, 53.2, 53.0, 49.8, 39.4, 38.9, 37.4, 36.5,
27.0, 22.3, 16.0. HRMS m/z calcd for C52H68N8O10S 996.48, found
997.5008 [M + H+].
(2S,4R)-N-(2-((14-(4-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-
dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)-
3,6,9,12-tetraoxatetradecyl)oxy)-4-(4-methylthiazol-5-yl)-
benzyl)-1-((S)-2-(1-ﬂuorocyclopropane-1-carboxamido)-3,3-
dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide (29).
A mixture of 41 (1 equiv), osmium tetroxide 4% in H2O (0.2 equiv),
sodium periodate (4 equiv), pyridine (2 equiv) in dioxane/H2O (3:1)
was stirred at rt for 48 h. Then H2O was added to the reaction and the
product was extracted with DCM. The organic phases were combined,
dried over MgSO4, ﬁltered, and evaporated to dryness. Then, following
general method A, from the aldehyde derivative and 1c compound 29
was obtained after puriﬁcation by HPLC using a gradient of 5% to 95%
v/v acetonitrile in 0.1% aqueous solution of ammonia as white powder.
Yield: 9.5 mg, 46%. 1H NMR (400 MHz, MeOD) δ: 9.54 (s, 1H), 8.90
(s, 1H), 8.70 (d, J = 5.8 Hz, 1H), 7.75 (s, 1H), 7.64 (dd, J = 0.6, 5.9 Hz,
1H), 7.51 (d, J = 7.6 Hz, 1H), 7.10−7.03 (m, 2H), 6.77 (s, 2H), 4.78 (s,
1H), 4.69−4.63 (m, 1H), 4.55−4.42 (m, 3H), 4.31−4.23 (m, 2H),
3.97−3.57 (m, 29H), 2.71−2.60 (m, 10H), 2.52 (s, 3H), 2.30−2.24 (m,
1H), 2.17−2.08 (m, 1H), 1.43−1.29 (m, 4H), 1.07 (s, 9H). 13C NMR
(101 MHz, MeOD) δ: 174.2, 171.6, 171.3, 163.0, 161.0, 158.0, 152.8,
151.7, 151.2, 149.1, 143.6, 138.8, 137.3, 133.5, 132.9, 130.0, 128.4,
122.8, 121.7, 119.4, 119.3, 113.8, 113.2, 106.5, 80.3, 78.0, 73.7, 71.8,
71.6, 71.5, 71.4, 71.0, 70.8, 69.6, 69.4, 62.2, 60.8, 58.7, 58.6, 58.2, 56.3,
54.0, 53.3, 39.5, 38.9, 37.4, 37.3, 26.9, 16.0, 14.1, 14.0, 13.9. HRMSm/z
calcd for C58H77FN8O12S 1128.54, found 1129.5445 [M + H
+].
(2S,4R)-1-((S)-2-(1-Cyanocyclopropane-1-carboxamido)-3,3-
dimethylbutanoyl)-N-(2-((14-(4-(2,6-dimethoxy-4-(2-methyl-
1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-
yl)-3,6,9,12-tetraoxatetradecyl)oxy)-4-(4-methylthiazol-5-yl)-
benzyl)-4-hydroxypyrrolidine-2-carboxamide (30). A mixture of
43 (1 equiv), osmium tetroxide 4% in H2O (0.2 equiv), sodium
periodate (4 equiv), pyridine (2 equiv) in dioxane/H2O (3:1) was
stirred at rt for 48 h. Then H2O was added to the reaction and the
product was extracted with DCM. The organic phases were combined,
dried over MgSO4, ﬁltered, and evaporated to dryness. Then, following
general method A, from the aldehyde derivative and 1c compound 30
was obtained after puriﬁcation by HPLC using a gradient of 5% to 95%
v/v acetonitrile in 0.1% aqueous solution of ammonia as white powder.
Yield: 9 mg, 39%. 1H NMR (400 MHz, MeOD) δ: 9.55 (d, J = 0.7 Hz,
1H), 8.89 (s, 1H), 8.70 (d, J = 5.9 Hz, 1H), 7.74 (s, 1H), 7.64 (dd, J =
0.7, 5.8 Hz, 1H), 7.49 (d, J = 7.7 Hz, 1H), 7.09−7.02 (m, 2H), 6.76 (s,
2H), 4.69−4.63 (m, 2H), 4.55−4.42 (m, 3H), 4.34−4.23 (m, 2H), 3.95
(t, J = 4.5 Hz, 2H), 3.89 (s, 6H), 3.84−3.75 (m, 6H), 3.73−3.70 (m,
5H), 3.69−3.58 (m, 9H), 2.68−2.56 (m, 10H), 2.52 (s, 3H), 2.32−2.22
(m, 1H), 2.17−2.09 (m, 1H), 1.71−1.55 (m, 4H), 1.06 (s, 9H). 13C
NMR (101 MHz, MeOD) δ: 174.1, 171.5, 167.2, 163.1, 161.0, 158.1,
152.8, 151.7, 151.2, 149.2, 143.7, 138.8, 137.2, 133.5, 133.0, 130.2,
128.4, 122.8, 121.7, 120.7, 119.5, 119.3, 113.9, 113.7, 106.5, 71.8, 71.6,
71.6, 71.4, 71.1, 70.9, 69.7, 69.4, 60.8, 59.5, 58.7, 58.1, 56.3, 54.2, 53.4,
39.6, 38.9, 37.4, 37.3, 26.8, 18.1, 18.0, 16.0, 14.9. HRMS m/z calcd for
C59H77N9O12S 1035.54, found 1036.5169 [M + H
+].
14-(4-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-
naphthyridin-4-yl)benzyl)piperazin-1-yl)-N-(2-((2-(2,6-dioxo-
piperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethyl)-
3,6,9,12-tetraoxatetradecanamide (31).Amixture of 45 (1 equiv),
osmium tetroxide 4% in H2O (0.2 equiv), sodium periodate (4 equiv),
pyridine (2 equiv) in dioxane/H2O (3:1) was stirred at rt for 48 h. Then
H2O was added to the reaction and the product was extracted with
DCM. The organic phases were combined, dried over MgSO4, ﬁltered,
and evaporated to dryness. Then, following general method A, from the
aldehyde derivative and 1c compound 31 was obtained after
puriﬁcation by HPLC using a gradient of 5% to 95% v/v acetonitrile
in 0.1% aqueous solution of formic acid as white powder. Yield: 3.7 mg,
17%. 1H NMR (400 MHz, MeOD) δ: 9.55 (d, J = 0.7 Hz, 1H), 8.90 (s,
1H), 8.70 (d, J = 5.8 Hz, 1H), 7.76 (s, 1H), 7.64 (dd, J = 0.6, 5.8 Hz,
1H), 7.52 (d, J = 7.7 Hz, 1H), 7.08−7.01 (m, 2H), 6.81 (s, 2H), 4.65−
4.60 (m, 2H), 4.53−4.41 (m, 3H), 4.27−4.25 (m, 2H), 4.02−3.61 (m,
29H), 2.96−2.76 (m, 10H), 2.51 (s, 3H), 2.27−2.21 (m, 1H), 2.15−
2.08 (m, 1H), 2.04 (s, 3H), 1.06 (s, 9H). 13CNMR (101MHz,MeOD)
δ: 174.4, 173.1, 172.3, 163.0, 161.0, 158.0, 152.8, 151.8, 151.3, 151.2,
149.1, 143.5, 139.0, 133.5, 132.8, 130.0, 128.4, 122.8, 121.7, 119.2,
119.1, 113.7, 106.6, 71.9, 71.6, 71.5, 71.4, 71.1, 70.9, 69.4, 60.7, 59.2,
58.1, 58.0, 56.6, 52.8, 49.8, 39.4, 38.9, 37.4, 36.5, 27.0, 22.3, 16.0.
HRMS m/z calcd for C56H76N8O12S 1084.53, found 1085.5658 [M +
H+].
2-(2-(Hex-5-en-1-yloxy)ethoxy)ethan-1-ol (33). To a suspen-
sion of NaH (2.5 equiv) in DMF (1 M) and THF (1 M), diethylene
glycol (5 equiv) was added at 0 °C under nitrogen. After 45 min 6-
bromo-1-hexene (1 equiv) was added dropwise at 0 °C. Then the ice
bath was removed, and the reaction mixture was stirred overnight at rt
under nitrogen. Distillate water was added, and the reaction mixture
was acidiﬁed with HCl 1M up to pH 2. The product was extracted with
CHCl3. The organic phases were combined, dried overMgSO4, ﬁltered,
and evaporated to dryness. The resulting oil was puriﬁed by ﬂash
column chromatography using a gradient from 50% to 100% of ethyl
acetate in heptane to obtain the desired compound 33 as an oil. Yield:
552 mg, 49%. 1H NMR (400 MHz, CDCl3) δ: 5.85−5.74 (m, 1H),
5.03−4.96 (m, 1H), 4.96−4.91 (m, 1H), 3.75−3.56 (m, 8H), 3.46 (t, J
= 6.7 Hz, 2H), 2.09−2.03 (m, 2H), 1.65−1.56 (m, 2H), 1.48−1.39 (m,
2H). 13C NMR (101 MHz, CDCl3) δ: 138.8, 114.7, 72.6, 71.5, 70.6,
70.3, 62.0, 33.6, 29.2, 25.5.
2-(2-(Hex-5-en-1-yloxy)ethoxy)acetic Acid (34). A mixture of
30 (1 equiv), BAIB (2.2 equiv), TEMPO (0.22 equiv) in ACN/H2O
(1:1) (0.5 M) was stirred overnight at rt. The day after the solvent was
evaporated, the crude was resuspended in DCM and washed with H2O.
The organic phases were combined, dried over MgSO4, ﬁltered, and
evaporated to dryness. The resulting product was puriﬁed by ﬂash
column chromatography using a gradient from 0% to 20% of MeOH in
DCM to obtain compound 34 as an oil. Yield: 472 mg, 81%. 1H NMR
(400 MHz, CDCl3) δ: 5.84−5.73 (m, 1H), 5.03−4.97 (m, 1H), 4.96−
4.92 (m, 1H), 4.15 (s, 2H), 3.76−3.73 (m, 2H), 3.63−3.59 (m, 2H),
3.52 (t, J = 6.6 Hz, 2H), 2.10−2.03 (m, 2H), 1.65−1.57 (m, 2H), 1.49−
1.40 (m, 2H). 13C NMR (101 MHz, CDCl3) δ: 173.2, 138.7, 114.8,
71.7, 71.6, 69.7, 69.1, 33.6, 28.9, 25.4.
(2R,4S)-1-((R)-2-(2-(2-(Hex-5-en-1-yloxy)ethoxy)acetamido)-
3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)-
benzyl)pyrrolidine-2-carboxamide (35). Following general meth-
od B, compound 35 was obtained from compounds 34 and 2a
(synthesized accordingly to literature61). The crude was puriﬁed by
HPLC using a gradient of 5% to 95% v/v acetonitrile in 0.1% aqueous
solution of formic acid to obtain 35 as white powder. Yield: 14.7 mg,
30%. 1HNMR (400MHz, CDCl3) δ: 8.64 (s, 1H), 7.28−7.23 (m, 4H),
5.74−5.63 (m, 1H), 4.93−4.82 (m, 2H), 4.65 (t, J = 7.9 Hz, 1H), 4.49−
4.21 (m, 4H), 4.03−3.85 (m, 3H), 3.59−3.47 (m, 5H), 3.40−3.34 (m,
2H), 2.47−2.39 (m, 4H), 2.06−1.91 (m, 3H), 1.54−1.45 (m, 2H),
1.37−1.29 (m, 2H), 0.87 (s, 9H). 13C NMR (101 MHz, CDCl3) δ:
171.6, 170.8, 150.7, 148.1, 138.7, 138.4, 132.0, 130.7, 129.6, 128.3,
114.8, 71.5, 71.4, 70.4, 70.3, 69.8, 58.6, 57.5, 56.7, 43.3, 36.0, 34.9, 33.6,
29.1, 26.5, 25.4, 16.0. MS m/z calcd for C32H46N4O6S 614.31, found
615.4 [M + H+].
2-(2-(Allyloxy)ethoxy)ethan-1-ol (38). To a mixture of NaOH
(1 equiv) in dioxane (0.3 M), diethylene glycol (2 equiv) and allyl
bromide (1 equiv) were added dropwise. The mixture was heated
overnight at 55 °C. Then the reaction mixture was dried over MgSO4,
ﬁltered, and evaporated in vacuum. The crude was puriﬁed by ﬂash
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column chromatography using a gradient from 50% to 100% of ethyl
acetate in heptane to obtain compound 38 as an oil. Yield: 329mg, 54%.
1H NMR (400 MHz, CDCl3) δ: 5.90−5.80 (m, 1H), 5.21 (qd, J = 1.6,
17.2 Hz, 1H), 5.14−5.10 (m, 1H), 3.96 (td, J = 1.4, 5.7 Hz, 2H), 3.68−
3.59 (m, 4H), 3.56−3.52 (m, 4H). 13C NMR (101 MHz, CDCl3) δ:
134.5, 117.3, 72.6, 72.2, 70.4, 69.4, 61.7.
3,6,9,12-Tetraoxapentadec-14-en-1-ol (39). Following the
same procedure applied for compound 38, from tetraethylene glycol
and allyl bromide compound 39 was obtained as oil. Yield: 3.29 g, 68%.
Analytical data matched those previously reported.75
(2S,4R)-N-(2-(2-(2-(Allyloxy)ethoxy)ethoxy)-4-(4-methyl-
thiazol-5-yl)benzyl)-1-((S)-2-(1-ﬂuorocyclopropane-1-carbox-
amido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-car-
boxamide (40). Following general method E, compound 40 was
obtained from compounds 38 and 2d (synthesis detailed in the
Supporting Information). The crude was puriﬁed by HPLC using a
gradient of 5% to 95% v/v acetonitrile in 0.1% aqueous solution of
formic acid. Yield: 21.7 mg, 42%. 1H NMR (500 MHz, MeOD) δ: 8.91
(s, 1H), 8.52 (t, J = 5.9Hz, 1H), 7.55 (dd, J = 3.4, 9.4 Hz, 1H), 7.51 (d, J
= 7.8 Hz, 1H), 7.10 (d, J = 1.6 Hz, 1H), 7.06 (dd, J = 1.6, 7.8 Hz, 1H),
5.98−5.90 (m, 1H), 5.30 (ddt, J = 1.7, 6.9, 8.6 Hz, 1H), 5.18 (ddt, J =
1.4, 4.5, 5.2 Hz, 1H), 4.79 (d, J = 9.6 Hz, 1H), 4.66 (t, J = 8.3 Hz, 1H),
4.54−4.43 (m, 3H), 4.31−4.26 (m, 2H), 4.07−4.04 (m, 2H), 3.97−
3.94 (m, 2H), 3.90−3.82 (m, 2H), 3.80−3.76 (m, 2H), 3.69−3.66 (m,
2H), 2.53 (s, 3H), 2.29−2.24 (m, 1H), 2.17−2.10 (m, 1H), 1.42−1.30
(m, 4H), 1.07 (s, 10H). MS m/z calcd for C33H45FN4O7S 660.30,
found 661.3 [M + H+].
(2S,4R)-N-(2-((3,6,9,12-Tetraoxapentadec-14-en-1-yl)oxy)-4-
(4-methylthiazol-5-yl)benzyl)-1-((S)-2-(1-ﬂuorocyclopropane-
1-carboxamido)-3 ,3-dimethylbutanoyl) -4-hydroxy-
pyrrolidine-2-carboxamide (41). Following general method E,
compound 41 was obtained from compounds 39 and 2d (synthesis
detailed in the Supporting Information). The crude was puriﬁed by
HPLC using a gradient of 5% to 95% v/v acetonitrile in 0.1% aqueous
solution of formic acid. Yield: 26.9 mg, 46%. 1H NMR (500 MHz,
MeOD) δ: 8.91 (s, 1H), 8.51 (t, J = 6.1 Hz, 1H), 7.56 (dd, J = 3.2, 9.6
Hz, 1H), 7.51 (d, J = 7.8 Hz, 1H), 7.10 (d, J = 1.6 Hz, 1H), 7.06 (dd, J =
1.7, 7.7 Hz, 1H), 5.97−5.89 (m, 1H), 5.30 (ddt, J = 1.7, 6.9, 8.7 Hz,
1H), 5.19−5.16 (m, 1H), 4.79 (d, J = 9.1 Hz, 1H), 4.66 (t, J = 8.2 Hz,
1H), 4.56−4.43 (m, 3H), 4.30−4.26 (m, 2H), 4.04−4.02 (m, 2H),
3.97−3.94 (m, 2H), 3.90−3.82 (m, 2H), 3.80−3.77 (m, 2H), 3.73−
3.70 (m, 2H), 3.69−3.64 (m, 7H), 3.62−3.59 (m, 2H), 2.54 (s, 3H),
2.30−2.25 (m, 1H), 2.16−2.11 (m, 1H), 1.42−1.31 (m, 4H), 1.07 (s,
9H). MS m/z calcd for C37H53FN4O9S 748.35, found 749.4 [M + H
+].
(2S,4R)-N-(2-(2-(2-(Allyloxy)ethoxy)ethoxy)-4-(4-methyl-
thiazol-5-yl)benzyl)-1-((S)-2-(1-cyanocyclopropane-1-carboxa-
mido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carbox-
amide (42). Following general method E, compound 42 was obtained
from compounds 38 and 2c (synthesized as previously reported29). The
crude was puriﬁed by HPLC using a gradient of 5% to 95% v/v
acetonitrile in 0.1% aqueous solution of formic acid. Yield: 15.8 mg,
61%. 1H NMR (500 MHz, MeOD) δ: 8.91 (s, 1H), 8.50 (t, J = 5.9 Hz,
1H), 7.50 (d, J = 7.9 Hz, 1H), 7.10 (d, J = 1.8 Hz, 1H), 7.06 (dd, J = 1.7,
8.0 Hz, 1H), 5.98−5.90 (m, 1H), 5.30 (ddt, J = 1.8, 6.9, 8.6 Hz, 1H),
5.20−5.16 (m, 1H), 4.71−4.64 (m, 2H), 4.54−4.44 (m, 4H), 4.31−
4.27 (m, 2H), 4.06 (td, J = 1.4, 5.6 Hz, 2H), 3.97−3.95 (m, 2H), 3.87−
3.78 (m, 5H), 3.69−3.66 (m, 3H), 2.53 (s, 4H), 2.28−2.23 (m, 1H),
2.16−2.10 (m, 1H), 1.71−1.56 (m, 4H), 1.06 (s, 9H). 13C NMR (101
MHz, MeOD) δ: 174.3, 171.6, 167.3, 158.2, 152.9, 149.2, 136.2, 133.6,
133.0, 130.2, 128.5, 122.9, 120.8, 117.4, 113.9, 73.2, 71.9, 71.1, 71.0,
70.7, 69.5, 60.9, 59.7, 59.6, 39.8, 39.0, 37.4, 26.9, 18.2, 18.1, 16.0, 15.0,
14.9. MS m/z calcd for C34H45N5O7S 667.30, found 668.4 [M + H
+].
(2S,4R)-N-(2-((3,6,9,12-Tetraoxapentadec-14-en-1-yl)oxy)-4-
(4-methylthiazol-5-yl)benzyl)-1-((S)-2-(1-cyanocyclopropane-
1-carboxamido)-3 ,3-dimethylbutanoyl) -4-hydroxy-
pyrrolidine-2-carboxamide (43). Following general method E,
compound 43was obtained from compounds 39 and 2c (synthesized as
previously reported29). The crude was puriﬁed by HPLC using a
gradient of 5% to 95% v/v acetonitrile in 0.1% aqueous solution of
formic acid. Yield: 15.3 mg, 52%. 1H NMR (500 MHz, MeOD) δ: 8.91
(s, 1H), 8.49 (t, J = 6.1Hz, 1H), 7.51 (d, J = 7.7Hz, 1H), 7.10 (d, J = 1.6
Hz, 1H), 7.06 (dd, J = 1.6, 7.7 Hz, 1H), 5.97−5.89 (m, 1H), 5.30 (ddt, J
= 1.6, 6.9, 8.6 Hz, 1H), 5.19−5.16 (m, 1H), 4.71−4.64 (m, 2H), 4.55−
4.43 (m, 3H), 4.31−4.26 (m, 2H), 4.03 (td, J = 1.4, 5.6 Hz, 2H), 3.97−
3.94 (m, 2H), 3.87−3.77 (m, 4H), 3.73−3.71 (m, 2H), 3.69−3.64 (m,
7H), 3.62−3.59 (m, 2H), 2.54 (s, 3H), 2.30−2.25 (m, 1H), 2.16−2.10
(m, 1H), 1.71−1.56 (m, 4H), 1.06 (s, 9H). MS m/z calcd for
C38H53N5O9S 755.36, found 756.5 [M + H
+].
(2S,4R)-1-((S)-2-Acetamido-3,3-dimethylbutanoyl)-N-(2-(2-
(2-(allyloxy)ethoxy)ethoxy)-4-(4-methylthiazol-5-yl)benzyl)-4-
hydroxypyrrolidine-2-carboxamide (44). Following general meth-
od E, compound 44 was obtained from compounds 38 and 2b
(synthesized accordingly to literature29). The crude was puriﬁed by
HPLC using a gradient of 5% to 95% v/v acetonitrile in 0.1% aqueous
solution of formic acid. Yield: 12.7 mg, 53%. 1H NMR (400 MHz,
MeOD) δ: 8.91 (s, 1H), 7.52 (d, J = 7.8Hz, 1H), 7.08 (s, 1H), 7.04 (dd,
J = 1.4, 7.8 Hz, 1H), 5.99−5.88 (m, 1H), 5.30 (dq, J = 1.7, 6.9 Hz, 1H),
5.18 (dq, J = 1.3, 4.5 Hz, 1H), 4.67−4.60 (m, 2H), 4.55−4.42 (m, 3H),
4.30−4.25 (m, 2H), 4.05 (dt, J = 1.4, 5.6 Hz, 2H), 3.97−3.90 (m, 3H),
3.85−3.77 (m, 3H), 3.68−3.65 (m, 2H), 2.53 (s, 3H), 2.28−2.20 (m,
1H), 2.16−2.07 (m, 1H), 2.03 (s, 3H), 1.06 (s, 9H). 13C NMR (101
MHz, MeOD) δ: 174.4, 173.1, 172.3, 158.0, 152.8, 149.1, 136.1, 133.5,
132.8, 130.0, 128.4, 122.8, 117.3, 114.0, 113.8, 73.1, 71.8, 70.9, 70.6,
69.4, 60.7, 59.1, 57.9, 39.4, 38.9, 36.5, 27.0, 22.3, 15.9. MSm/z calcd for
C31H44N4O7S 616.29, found 617.4 [M + H
+].
(2S,4R)-N-(2-((3,6,9,12-Tetraoxapentadec-14-en-1-yl)oxy)-4-
(4-methylthiazol-5-yl)benzyl)-1-((S)-2-acetamido-3,3-dime-
thylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide (45). Fol-
lowing general method E, compound 45was obtained from compounds
39 and 2b (synthesized accordingly to literature29). The crude was
puriﬁed byHPLC using a gradient of 5% to 95% v/v acetonitrile in 0.1%
aqueous solution of formic acid. Yield: 13.8 mg, 53%. 1H NMR (400
MHz, MeOD) δ: 8.92 (s, 1H), 7.52 (d, J = 7.9 Hz, 1H), 7.08 (s, 1H),
7.04 (dd, J = 1.5, 7.8 Hz, 1H), 6.01−5.88 (m, 1H), 5.29 (dq, J = 1.7, 6.9
Hz, 1H), 5.17 (dq, J = 1.3, 4.5 Hz, 1H), 4.67−4.60 (m, 2H), 4.56−4.39
(m, 2H), 4.29−4.25 (m, 2H), 4.03 (dt, J = 1.4, 5.7 Hz, 2H), 3.97−3.90
(m, 3H), 3.85−3.76 (m, 3H), 3.73−3.63 (m, 9H), 3.62−3.58 (m, 2H),
2.53 (s, 3H), 2.28−2.21 (m, 1H), 2.16−2.08 (m, 1H), 2.04 (s, 3H),
1.06 (s, 9H). 13C NMR (101 MHz, MeOD) δ: 174.4, 173.1, 172.2,
158.0, 152.8, 149.1, 136.1, 133.5, 132.8, 130.0, 128.4, 122.8, 117.2,
113.7, 73.1, 71.8, 71.6, 71.5, 71.1, 70.8, 70.6, 69.4, 60.7, 59.1, 58.0, 39.4,
38.9, 36.5, 27.0, 22.3, 15.9. MS m/z calcd for C35H52N4O9S 704.35,
found 705.4 [M + H+].
(2S,4R)-N-(2-(2-(2-(4-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-
dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)ethoxy)-
ethoxy)-4-(4-methylthiazol-5-yl)benzyl)-1-((S)-2-(1-ﬂuorocy-
clopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hy-
droxypyrrolidine-2-carboxamide (46). Following general method
C, from 69 (0.033 mmol) and 1c (0.033 mmol) compound 46 was
obtained after puriﬁcation by HPLC using a gradient of 5% to 95% v/v
acetonitrile in 0.1% aqueous solution of formic acid as white powder.
Yield: 5.3 mg, 16%. 1H NMR (400 MHz, MeOD) δ: 9.61 (s, 1H), 8.95
(s, 1H), 8.71 (d, J = 6.2 Hz, 1H), 7.97 (s, 1H), 7.85 (d, J = 6.0 Hz, 1H),
7.53 (d, J = 8.2 Hz, 1H), 7.10−7.07 (m, 2H), 6.90 (s, 2H), 4.78 (s, 1H),
4.66 (t, J = 8.5 Hz, 1H), 4.54−4.44 (m, 3H), 4.32−4.29 (m, 2H), 4.00−
3.81 (m, 14H), 3.76 (s, 3H), 3.55 (s, 4H), 3.45 (s, 4H), 3.30−3.27 (m,
2H), 2.53 (s, 3H), 2.32−2.26 (m, 1H), 2.18−2.10 (m, 1H), 1.44−1.30
(m, 4H), 1.08 (s, 9H). 13C NMR (101 MHz, MeOD) δ: 174.2, 171.8,
164.4, 162.2, 161.2, 157.8, 153.0, 149.0, 146.4, 142.3, 140.0, 133.5,
132.9, 129.9, 128.2, 122.9, 122.3, 120.8, 118.2, 113.5, 106.8, 80.3, 78.0,
71.0, 70.9, 69.1, 67.2, 60.9, 58.8, 58.7, 58.2, 57.5, 56.9, 50.7, 50.1, 39.4,
39.0, 37.6, 37.3, 26.9, 15.8, 14.1, 14.0, 14.0, 13.9. HRMS m/z calcd for
C52H65FN8O9S 996.46, found 997.4810 [M + H
+].
(2S,4R)-N-(2-(2-(2-(4-(2,5-Dimethoxy-4-(2-methyl-1-oxo-1,2-
dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)ethoxy)-
ethoxy)-4-(4-methylthiazol-5-yl)benzyl)-1-((S)-2-(1-ﬂuoro-
cyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-
hydroxypyrrolidine-2-carboxamide (47). Following general meth-
od C, from 69 (0.033 mmol) and 1d (synthesis detailed in the
Supporting Information) (0.033 mmol) compound 47 was obtained
after puriﬁcation by HPLC using a gradient of 5% to 95% v/v
acetonitrile in 0.1% aqueous solution of formic acid as white powder.
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Yield: 5.3mg, 5%. 1HNMR (400MHz,MeOD) δ: 9.52 (s, 1H), 8.91 (s,
1H), 8.62 (d, J = 5.7 Hz, 1H), 7.65 (s, 1H), 7.51 (d, J = 7.9 Hz, 1H),
7.23−7.19 (m, 2H), 7.10 (d, J = 1.2 Hz, 1H), 7.06 (dd, J = 1.6, 7.7 Hz,
1H), 6.98 (s, 1H), 4.78 (s, 1H), 4.66 (t, J = 8.5 Hz, 1H), 4.55−4.45 (m,
3H), 4.32−4.28 (m, 2H), 3.95−3.89 (m, 2H), 3.88−3.80 (m, 7H),
3.76−3.71 (m, 8H), 2.78−2.71 (m, 10H), 2.53 (s, 3H), 2.30−2.24 (m,
1H), 2.17−2.11 (m, 1H), 1.42−1.31 (m, 4H), 1.07 (s, 9H). 13C NMR
(101 MHz, MeOD) δ: 174.1, 171.7, 163.3, 158.0, 153.7, 152.8, 151.4,
150.6, 144.2, 139.2, 133.5, 133.0, 128.4, 124.1, 122.8, 121.5, 120.3,
115.8, 113.9, 80.3, 71.0, 70.8, 69.8, 69.3, 60.8, 58.7, 58.2, 56.7, 56.5,
54.3, 53.5, 39.4, 38.9, 37.4, 37.3, 26.9, 15.9, 14.1, 14.0, 13.9. HRMSm/z
calcd for C52H65FN8O9S 996.46, found 997.4712 [M + H
+].
(2S,4R)-N-(2-((5-(4-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-
dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)pentyl)-
oxy)-4-(4-methylthiazol-5-yl)benzyl)-1-((S)-2-(1-ﬂuoro-
cyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-
hydroxypyrrolidine-2-carboxamide (51, VZ185). Following
general method C, from 70 (0.02 mmol) and 1c (0.02 mmol)
compound 51was obtained after puriﬁcation by HPLC using a gradient
of 5% to 95% v/v acetonitrile in 0.1% aqueous solution of formic acid as
white powder. Yield: 4.8 mg, 24%. 1HNMR (400MHz,MeOD) δ: 9.56
(d, J = 0.8 Hz, 1H), 8.92 (s, 1H), 8.71 (d, J = 5.8 Hz, 1H), 7.78 (s, 1H),
7.65 (dd, J = 0.7, 5.8 Hz, 1H), 7.52 (d, J = 7.7 Hz, 1H), 7.07−7.03 (m,
2H), 6.86 (s, 2H), 4.79 (s, 1H), 4.67 (t, J = 12.4 Hz, 1H), 4.55−4.47
(m, 3H), 4.18 (s, 2H), 4.14 (t, J = 6.0Hz, 2H), 3.96−3.82 (m, 8H), 3.74
(s, 3H), 3.18−2.78 (m, 10H), 2.53 (s, 3H), 2.32−2.25 (m, 1H), 2.19−
2.12 (m, 1H), 1.98−1.91 (m, 2H), 1.79−1.71 (m, 2H), 1.68−1.61 (m,
2H), 1.42−1.29 (m, 4H), 1.08 (s, 9H). 13C NMR (101 MHz, MeOD)
δ: 174.2, 171.8, 171.4, 163.1, 161.0, 158.0, 152.8, 151.7, 151.2, 149.1,
143.6, 138.8, 133.6, 132.8, 129.7, 128.0, 122.5, 121.7, 119.2, 113.1,
106.6, 80.3, 78.0, 71.0, 69.2, 60.8, 59.2, 58.7, 58.1, 56.4, 53.1, 49.8, 39.3,
38.9, 37.4, 37.3, 30.1, 26.9, 25.1, 15.9, 14.1, 14.0, 13.8. HRMSm/z calcd
for C53H67FN8O8S 994.48, found 995.5024 [M + H
+].
(2S,4R)-N-(2-((5-(4-(2,5-Dimethoxy-4-(2-methyl-1-oxo-1,2-
dihydro-2,7-naphthyridin-4-yl)benzyl)piperazin-1-yl)pentyl)-
oxy)-4-(4-methylthiazol-5-yl)benzyl)-1-((S)-2-(1-ﬂuoro-
cyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-
hydroxypyrrolidine-2-carboxamide (52). Following general meth-
od C, from 70 (0.02 mmol) and 1d (0.02 mmol) compound 52 was
obtained after puriﬁcation by HPLC using a gradient of 5% to 95% v/v
acetonitrile in 0.1% aqueous solution of formic acid as white powder.
Yield: 4 mg, 20%. 1HNMR (400MHz,MeOD) δ: 9.53 (s, 1H), 8.92 (s,
1H), 8.62 (d, J = 5.7 Hz, 1H), 7.65 (s, 1H), 7.53 (d, J = 7.4 Hz, 1H),
7.23−7.19 (m, 2H), 7.05 (s, 2H), 7.02 (s, 1H), 4.79 (s, 1H), 4.68 (t, J =
8.4 Hz, 1H), 4.55−4.47 (m, 3H), 4.15 (t, J = 5.9 Hz, 2H), 3.92−3.82
(m, 7H), 3.75 (s, 3H), 3.72 (s, 3H), 3.18−2.91 (m, 10H), 2.53 (s, 3H),
2.32−2.26 (m, 1H), 2.19−2.12 (m, 1H), 2.00−1.93 (m, 2H), 1.87−
1.78 (m, 2H), 1.70−1.62 (m, 2H), 1.43−1.30 (m, 4H), 1.08 (s, 9H).
13C NMR (101 MHz, MeOD) δ:174.2, 171.8, 163.3, 157.9, 153.7,
152.8, 151.4, 150.5, 149.2, 144.1, 139.3, 133.6, 132.9, 129.6, 127.9,
122.6, 121.5, 120.1, 116.0, 115.6, 113.1, 80.4, 78.1, 71.0, 69.0, 60.9,
58.7, 58.4, 58.2, 56.8, 56.5, 56.2, 53.1, 51.8, 39.3, 38.9, 37.4, 37.3, 29.8,
26.9, 24.7, 15.9, 14.1, 14.0, 13.9. HRMS m/z calcd for C53H67FN8O8S
994.48, found 995.4771 [M + H+].
(2S,4R)-N-(2-(2-(2-((1-(2,6-Dimethoxy-4-(2-methyl-1-oxo-
1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)azetidin-3-yl)-
amino)-2-oxoethoxy)ethoxy)-4-(4-methylthiazol-5-yl)benzyl)-
1-((S)-2-(1-ﬂuorocyclopropane-1-carboxamido)-3,3-dimethyl-
butanoyl)-4-hydroxypyrrolidine-2-carboxamide (55). Following
general method B, from the 71 (0.02 mmol) and 1e (0.02 mmol)
compound 55was obtained after puriﬁcation by HPLC using a gradient
of 5% to 95% v/v acetonitrile in 0.1% aqueous solution of ammonia as
white powder. Yield: 2.4 mg, 12%. 1HNMR (400MHz,MeOD) δ: 9.56
(d, J = 0.6 Hz, 1H), 8.93 (s, 1H), 8.71 (d, J = 6.0 Hz, 1H), 7.80 (s, 1H),
7.63 (dd, J = 0.6, 5.8 Hz, 1H), 7.55 (d, J = 8.1 Hz, 1H), 7.12−7.08 (m,
2H), 6.89 (s, 2H), 4.80−4.64 (m, 3H), 4.60−4.31 (m, 11H), 4.23 (s,
2H), 4.06 (t, J = 4.0 Hz, 2H), 3.98 (s, 6H), 3.91−3.80 (m, 2H), 3.74 (s,
3H), 2.53 (s, 3H), 2.31−2.25 (m, 1H), 2.18−2.10 (m, 1H), 1.42−1.30
(m, 4H), 1.07 (s, 9H). 13C NMR (101 MHz, MeOD) δ: 174.3, 171.8,
166.7, 160.7, 157.8, 152.9, 151.8, 151.3, 149.2, 143.3, 140.4, 139.2,
133.4, 133.0, 130.0, 128.2, 123.0, 121.7, 119.1, 118.6, 113.4, 106.8, 71.5,
71.5, 71.0, 69.2, 60.9, 60.9, 58.7, 58.2, 56.9, 49.5, 39.4, 38.9, 37.5, 37.3,
29.5, 26.9, 15.9, 13.9. HRMS m/z calcd for C51H61FN8O10S 996.42,
found 997.4452 [M + H+].
(2S,4R)-N-(2-(2-(2-((1-(2,5-Dimethoxy-4-(2-methyl-1-oxo-
1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)azetidin-3-yl)-
amino)-2-oxoethoxy)ethoxy)-4-(4-methylthiazol-5-yl)benzyl)-
1-((S)-2-(1-ﬂuorocyclopropane-1-carboxamido)-3,3-dimethyl-
butanoyl)-4-hydroxypyrrolidine-2-carboxamide (56). Following
general method B, from 71 (0.02 mmol) and 1f (synthesis detailed in
the Supporting Information) (0.02 mmol) compound 56 was obtained
after puriﬁcation by HPLC using a gradient of 5% to 95% v/v
acetonitrile in 0.1% aqueous solution of ammonia as white powder.
Yield: 3.3 mg, 17%. 1H NMR (400 MHz, MeOD) δ: 9.39 (s, 1H), 8.80
(s, 1H), 8.49 (d, J = 5.7 Hz, 1H), 7.54 (s, 1H), 7.42 (d, J = 8.2 Hz, 1H),
7.10 (s, 1H), 7.04 (d, J = 5.6 Hz, 1H), 6.99 (s, 1H), 6.98−6.94 (m, 2H),
4.66 (s, 1H), 4.60−4.51 (m, 2H), 4.45−4.32 (m, 5H), 4.27−4.15 (m,
6H), 4.10 (s, 2H), 3.93 (t, J = 4.1 Hz, 2H), 3.81 (s, 3H), 3.78−3.67 (m,
2H), 3.63 (s, 3H), 3.58 (s, 3H), 2.40 (s, 3H), 2.19−2.10 (m, 1H),
2.05−1.98 (m, 1H), 1.30−1.16 (m, 4H), 0.94 (s, 9H). 13C NMR (101
MHz, MeOD) δ: 174.2, 173.2, 171.8, 167.1, 166.6, 163.2, 157.8, 153.4,
153.0, 152.9, 151.4, 150.6, 149.2, 143.8, 139.5, 133.4, 133.0, 130.0,
128.2, 127.1, 123.0, 121.5, 120.9, 120.0, 116.1, 115.6, 113.4, 80.3, 78.0,
71.5, 71.5, 71.0, 69.2, 69.1, 60.9, 58.7, 58.2, 56.8, 56.6, 55.9, 49.5, 49.5,
40.7, 39.4, 38.9, 37.4, 37.3, 26.9, 15.9, 14.0. HRMS m/z calcd for
C51H61FN8O10S 996.42, found 997.4435 [M + H
+].
(2S,4R)-N-(2-((5-((1-(2,6-Dimethoxy-4-(2-methyl-1-oxo-1,2-
dihydro-2,7-naphthyridin-4-yl)benzyl)azetidin-3-yl)amino)-5-
oxopentyl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-1-((S)-2-(1-
ﬂuorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-
4-hydroxypyrrolidine-2-carboxamide (61). Following general
method B, from 72 (0.025 mmol) and 1e (0.025 mmol) compound
61 was obtained after puriﬁcation by HPLC using a gradient of 5% to
95% v/v acetonitrile in 0.1% aqueous solution of formic acid as white
powder. Yield: 4.5 mg, 18%. 1H NMR (400 MHz, MeOD) δ: 9.45 (d, J
= 0.5 Hz, 1H), 8.81 (s, 1H), 8.61 (d, J = 5.7 Hz, 1H), 7.68 (s, 1H), 7.54
(d, J = 5.5 Hz, 1H), 7.41 (d, J = 7.6 Hz, 1H), 6.96−6.91 (m, 2H), 6.74
(s, 2H), 4.69 (s, 1H), 4.58 (t, J = 8.5 Hz, 1H), 4.54−4.32 (m, 5H), 4.24
(s, 2H), 4.11−4.01 (m, 4H), 3.85 (s, 6H), 3.81−3.70 (m, 3H), 3.63 (s,
3H), 2.42 (s, 3H), 2.28 (t, J = 6.5 Hz, 2H), 2.21−2.15 (m, 1H), 2.08−
2.01 (m, 1H), 1.85−1.78 (m, 4H), 1.32−1.20 (m, 4H), 0.96 (s, 9H).
13C NMR (101 MHz, MeOD) δ: 176.1, 174.3, 171.7, 163.0, 160.7,
157.9, 152.8, 151.7, 151.3, 149.1, 148.6, 143.4, 139.4, 139.1, 133.6,
132.8, 129.7, 128.2, 128.0, 122.5, 121.7, 120.9, 119.2, 118.9, 113.0,
106.7, 80.3, 78.0, 71.0, 68.8, 61.1, 60.8, 58.7, 58.2, 56.7, 56.1, 40.9, 39.3,
38.9, 37.4, 37.3, 36.4, 29.8, 29.5, 26.9, 23.4, 15.9, 14.1, 14.0, 13.9.
HRMS m/z calcd for C52H63FN8O9S 994.44, found 995.4634 [M +
H+].
(2S,4R)-N-(2-((5-((1-(2,5-Dimethoxy-4-(2-methyl-1-oxo-1,2-
dihydro-2,7-naphthyridin-4-yl)benzyl)azetidin-3-yl)amino)-5-
oxopentyl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-1-((S)-2-(1-
ﬂuorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-
4-hydroxypyrrolidine-2-carboxamide (62). Following general
method B, from 72 (0.025 mmol) and 1f (0.025 mmol) compound
62 was obtained after puriﬁcation by HPLC using a gradient of 5% to
95% v/v acetonitrile in 0.1% aqueous solution of formic acid as white
powder. Yield: 5.8 mg, 23%. 1H NMR (400 MHz, MeOD) δ: 9.51 (d, J
= 0.7 Hz, 1H), 8.91 (s, 1H), 8.62 (d, J = 6.0 Hz, 1H), 7.64 (s, 1H), 7.52
(d, J = 7.5 Hz, 1H), 7.19 (dd, J = 0.8, 5.8 Hz, 1H), 7.14 (s, 1H), 7.06−
7.02 (m, 2H), 7.01 (s, 1H), 4.79 (s, 1H), 4.69 (t, J = 8.5 Hz, 1H), 4.58−
4.43 (m, 4H), 4.13 (s, 2H), 4.01−3.81 (m, 10H), 3.74 (s, 3H), 3.71 (s,
3H), 3.47 (s, 1H), 2.52 (s, 3H), 2.36 (t, J = 6.5 Hz, 2H), 2.31−2.24 (m,
1H), 2.20−2.11 (m, 1H), 1.92 (t, J = 2.6 Hz, 4H), 1.46−1.29 (m, 4H),
1.08 (s, 9H). 13C NMR (101 MHz, MeOD) δ: 175.8, 174.3, 171.7,
171.6, 171.4, 163.2, 157.9, 153.2, 152.8, 152.8, 151.3, 150.5, 149.1,
144.1, 139.3, 133.6, 132.8, 129.7, 128.0, 124.7, 122.5, 121.5, 120.2,
116.1, 115.6, 115.0, 113.0, 80.3, 78.0, 71.1, 68.8, 61.8, 60.8, 58.7, 58.2,
57.2, 56.6, 56.5, 41.4, 39.3, 38.9, 37.4, 37.3, 36.4, 29.8, 26.9, 23.5, 15.9,
14.1, 14.0, 13.9. HRMS m/z calcd for C52H63FN8O9S 994.44, found
995.4664 [M + H+].
(2S,4R)-N-(2-(2-(2,2-Diethoxyethoxy)ethoxy)-4-(4-methyl-
thiazol-5-yl)benzyl)-1-((S)-2-(1-ﬂuorocyclopropane-1-carbox-
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.8b01413
J. Med. Chem. XXXX, XXX, XXX−XXX
U
amido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-car-
boxamide (67). Following general method E, compound 67 was
obtained after reaction between 2-(2,2-diethoxyethoxy)ethan-1-ol
(synthesized accordingly to literature76) and 2d as white powder.
Yield: 92 mg, 87%. 1H NMR (400 MHz, CDCl3) δ: 8.66 (s, 1H), 7.31
(d, J = 7.7Hz, 1H), 6.95 (dd, J = 1.2, 7.7 Hz, 1H), 6.88 (s, 1H), 4.66 (t, J
= 7.6 Hz, 2H), 4.55−4.40 (m, 4H), 4.23−4.13 (m, 2H), 3.97−3.87 (m,
3H), 3.71−3.49 (m, 7H), 2.50 (s, 3H), 2.44−2.34 (m, 1H), 2.13−2.05
(m, 1H), 1.35−1.26 (m, 4H), 1.18 (t, J = 7.1 Hz, 6H), 0.93 (s, 9H). 13C
NMR (101 MHz, CDCl3) δ: 170.8, 170.3, 170.1, 156.9, 150.4, 148.6,
132.4, 131.8, 129.8, 126.9, 122.1, 112.9, 101.0, 79.5, 72.0, 70.3, 70.1,
68.0, 62.5, 62.3, 58.7, 57.5, 56.7, 39.1, 36.5, 35.6, 26.4, 16.2, 15.4, 13.9,
13.8, 13.7. MS m/z calcd for C34H49FN4O8S 692.33, found 693.3 [M +
H+].
(2S,4R)-N-(2-((5,5-Dimethoxypentyl)oxy)-4-(4-methylthia-
zol-5-yl)benzyl)-1-((S)-2-(1-ﬂuorocyclopropane-1-carboxami-
do)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxa-
mide (68). A mixture of 2d (0.075 mmol, 1 equiv), 5-bromo-1,1-
dimethoxypentane 66 (synthesized accordingly to literature77) (0.112
mmol, 1.8 equiv), and K2CO3 (0.225 mmol, 3 equiv) in DMF (0.5 mL)
was stirred at 70 °C overnight. The reaction mixture was diluted with
water and extracted with DCM, dried over MgSO4, ﬁltered and
evaporated to dryness. The crude was puriﬁed by ﬂash column
chromatography using a gradient from 0% to 20% of methanol in DCM
to obtain the desired compound as white powder. Yield: 23 mg, 55%.
1H NMR (400 MHz, MeOD) δ: 8.91 (s, 1H), 7.51 (d, J = 8.0 Hz, 1H),
7.05 (d, J = 1.5 Hz, 1H), 7.03 (s, 1H), 4.80 (d, J = 8.6 Hz, 1H), 4.68 (t, J
= 8.3 Hz, 1H), 4.57−4.42 (m, 4H), 4.11 (t, J = 6.2 Hz, 2H), 3.81−3.62
(m, 2H), 3.36 (s, 6H), 2.53 (s, 3H), 2.31−2.25 (m, 1H), 2.21−2.14 (m,
1H), 1.95−1.88 (m, 2H), 1.76−1.68 (m, 2H), 1.67−1.58 (m, 2H),
1.38−1.29 (m, 4H), 1.08 (s, 9H). 13C NMR (101 MHz, MeOD) δ:
174.2, 171.7, 171.4, 158.0, 152.8, 149.1, 133.6, 132.8, 129.6, 127.9,
122.4, 113.0, 106.2, 80.3, 71.1, 69.2, 60.8, 58.1, 55.8, 53.5, 43.8, 39.3,
38.9, 37.3, 33.4, 30.1, 26.9, 22.3, 15.9, 14.1, 14.0, 13.9, 13.2. MS m/z
calcd for C33H47FN4O7S 662.31, found 663.5 [M + H
+].
(2S,4R)-1-((S)-2-(1-Fluorocyclopropane-1-carboxamido)-
3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)-
2-(2-(2-oxoethoxy)ethoxy)benzyl)pyrrolidine-2-carboxamide
(69). Following general method F, compound 69was obtained from 67
(0.066 mmol) and directly used in the next step without any further
puriﬁcation. MS m/z calcd for C30H39FN4O7S 618.15, found 619.3 [M
+ H+].
(2S,4R)-1-((S)-2-(1-Fluorocyclopropane-1-carboxamido)-
3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)-
2-((5-oxopentyl)oxy)benzyl)pyrrolidine-2-carboxamide (70).
Following general method F, compound 70 was obtained from 68
(0.04 mmol) and directly used in the next step without any further
puriﬁcation. MS m/z calcd for C31H41FN4O6S 616.27, found 617.3 [M
+ H+].
2-(2-(2-(((2S,4R)-1-((S)-2-(1-Fluorocyclopropane-1-carboxa-
mido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-
carboxamido)methyl)-5-(4-methylthiazol-5-yl)phenoxy)-
ethoxy)acetic Acid (71). Following general method G, compound 71
was obtained from compound 69 (0.04 mmol) and was used in the next
step without any further puriﬁcation. Quantitative yield. MS m/z calcd
for C30H39FN4O8S 634.25, found 635.3 [M + H
+].
5-(2-(((2S,4R)-1-((S)-2-(1-Fluorocyclopropane-1-carboxami-
do)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-
carboxamido)methyl)-5-(4-methylthiazol-5-yl)phenoxy)-
pentanoic Acid (72). Following general methodG, compound 72was
obtained from compound 70 (0.05mmol) and was used in the next step
without any further puriﬁcation. Quantitative yield. MS m/z calcd for
C31H41FN4O7S 632.27, found 633.3 [M + H
+].
Biology. Cell Culture. Human cell lines HeLa and Hek293 were
purchased from ATCC and propagated in DMEM medium (Gibco),
supplemented with 10% fetal bovine serum (FBS) (Gibco), L-
glutamine (Gibco), 100 μg mL−1 of penicillin/streptomycin. RI-1
cells, purchased from DSMZ, were propagated in RPMI medium
(Gibco), supplemented with 10% fetal bovine serum (FBS) (Gibco), L-
glutamine, 100 μg mL−1 of penicillin/streptomycin. Cells were kept at
37 °C and 5% of CO2. EOL-1 and A-204 cell lines were purchased from
ATCC and DSMZ. EOL-1 cells were grown in RPMI supplemented
with 10% fetal calf serum. A-204 cells were grown in McCoy’s medium
supplemented with 10% fetal calf serum. All cell lines were routinely
tested for mycoplasma contamination using MycoAlert kit from Lonza.
Testing Compounds in Cells. HeLa and Hek293 cells were
seeded at either 0.3 × 106 or 0.5 × 106 cells per well in 6-well plate in 2
mL of medium. At 80% conﬂuency, cells were treated with compounds
at the desired concentration, with ﬁnal DMSO concentration of 0.1% v/
v. Cells were incubated at 37 °C and 5% of CO2 for the desired time
before harvesting. For protein extraction from adherent cells, cells were
washed twice with DPBS (Gibco) and lysed with RIPA buﬀer (Sigma-
Aldrich), supplemented with cOmplete Mini EDTA-free protease
inhibitor cocktail (Roche). Insoluble material was removed by
centrifugation at 14 000 rpm for 15 min at 4 °C. Supernatant was
collected and protein concentration was quantiﬁed by Bradford assay
(Thermo Scientiﬁc no. 23200, mean of two replicates). For RI-1 cells,
(1−1.5)× 106 cells/mL were seeded in 6-well plate in 2 mL of medium.
The day after, cells were treated with compounds at the desired
concentration, with ﬁnal DMSO concentration of 0.1% v/v. Before
harvesting, cells were incubated at 37 °C and 5% CO2 for the desired
time. Cells were washed twice with DPBS (Gibco) and lysed with RIPA
buﬀer (Sigma-Aldrich), supplemented with cOmplete Mini EDTA-free
protease inhibitor cocktail (Roche). Lysates were sonicated (10 s) and
centrifuged at 14 000 rpm for 20 min at 4 °C. Supernatant was
collected, and protein concentration was quantiﬁed by Bradford assay
(mean of two replicates). For EOL-1 and A-204 cell line, 20 000 cells
were seeded in 300 μL per well in a 24-well plate and incubated at 37 °C
overnight. Compounds were added from DMSO stock solution using a
digital dispenser D300 (Tecan), normalizing for added DMSO, and
cells were incubated at 37 °C for 18 h. Medium was removed, and cells
were washed with PBS and lysed in 80 μL of lysis buﬀer (1%Triton, 350
mM KCl, 10 mM Tris, pH 7,4, phosphatase-protease inhibitor cocktail
(Thermo Scientiﬁc no. 1861281), 10 mM DTT, Benzonase 0.5 μL/ml
(Novagen no. 70746 10KU, 25 U/μL)) for 30 min on ice before
insoluble debris was pelleted by centrifugation.
Small Interfering RNA. HeLa cells were seeded at 0.3 × 106 cells
per well in 6-well plates in 2 mL of medium, with a goal to achieve 70%
of conﬂuence on the day of transfection. BRD7, BRD9, and CRBN
targeting siRNA (L-020297-00-0005 ON-TARGETplus human BRD7,
L-014250-02-0005 ON-TARGETplus human BRD9, and L-021086-
00-0005 ON-TARGETplus human CRBN SMARTpool, 5 nmol,
Dharmacon) were prepared as a 20 μM solution in RNase-free 1×
siRNA buﬀer (Dharmacon). Nontargeting siRNA (On-TARGETplus
control pool, nontargeting pool D-001810-10-05, 5 nmol, Dharmacon)
was used as negative control. Medium was replaced on the day of
transfection. siRNA solution (5 μL) of BRD7, BRD9, or CRBN
targeting siRNA, negative control, and vehicle control (1× siRNA
buﬀer) were added to 250 μL of Opti-mem (Gibco), prepared in
duplicate. Lipofectamine RNAiMax (5 μL, Thermo Fisher Scientiﬁc)
was added to 250 μL of Opti-mem in another tube, also in duplicate.
The two solutions were combined, incubated for 20 min at rt, and
added to the wells. Plates were incubated at 37 °C and 5% CO2 for 48 h
before harvesting as described above.
Mechanistic Evaluation. Cells were seeded in 6-well plates with 5
× 105 cells per well in 2 mL of complete medium to aim for 80%
conﬂuence on the day of treatment. At time zero, ML4924 was added at
ﬁnal concentration of 3 μMwith 0.1% v/v of DMSO. DMSOwas added
to the remaining wells in order to match concentration of vehicle in all
wells. After 3 h,MG132 (50 μM) or VH298 (100 μM)was added to the
designated wells at a ﬁnal concentration of 0.1% v/v of DMSO. Again,
DMSO was added to the remaining wells to match vehicle
concentration. At t = 3.5 h, VZ185 or cisVZ185 was added at 100
nM and 0.1% v/v of DMSO, matching the DMSO concentration in the
remaining wells (ﬁnal concentration 0.3% v/v). Plates were incubated
for an additional 4 h at 37 °C and 5% CO2 before harvesting as
described before. The experiment was performed in duplicate.
Immunoblotting. Proteins were resolved by SDS−PAGE on
NuPage 4−12% Bis-Tris Midi Gel (Invitrogen) and transferred to
Amersham Protran 0.45NC nitrocellulose membrane (GEHealthcare)
using wet transfer. The membrane was blocked with 5% w/v milk in
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Tris-buﬀered saline (TBS) with 0.1% w/v Tween-20. The following
primary antibodies at the given concentration were used: anti β-actin
(Cell Signaling Technology, 4970S, 13E5) 1:2000, anti-Brd9 (Bethyl
A303-781A) 1:1000, anti-Brd7 (Bethyl A302-304A) 1:1000, VHL
rabbit Ab (Cell Signaling Technology, no. 68547S) 1:1000, anti-CRBN
(Novus Bio, NBP 1-9-1810) 1:1000, anti-actin hFAB rhodamine
antibody, Bio-Rad, no. 12004164. Following incubation with horse-
radish peroxidase-conjugated secondary antibody (Cell Signaling
Technology) or IRDye secondary antibody (Licor), bands were
developed using Amersham ECL Prime Western blotting detection kit
on AmershamHyperﬁlm ECL ﬁlm (Amersham) or ChemiDoc imaging
system (Bio-Rad). ImageJ software was used for band quantiﬁcation,
and the last was reported as relative amount as ratio of each protein
band relative to the lane’s loading control. Then the values obtained
were normalized to 0.1% DMSO vehicle control. Alternatively, protein
levels were determined on a WES capillary electrophoresis instrument
(Proteinsimple) using a BRD9 antibody (Bethyl A303-781A) and a
GAPDH antibody (Abcam no. ab9485) for normalization. DC50 and
half-lives were determined by assuming a linear model between the two
data points across 50% protein level mark.
Proliferation Assays. A-204 cells (1× 103) were seeded per well of
384-well plates. After overnight incubation, compounds were added to
the cells at logarithmic dose series using the HP digital dispenser D300
(Tecan), normalizing for added DMSO. 1 day and 8 days after seeding
cellular ATP content was measured using CellTiterGlo (Promega).
Measurements after 8 days were divided by themeasurement after 1 day
(i.e., the T0 plate) to derive fold proliferation. Data were analyzed with
GraphPad Prism software to obtain EC50 values.
MSProteomics. Sample Preparation.RI-1 cells were seeded at 2×
106 cells/mL in a 10 cm plate 12 h before treatment. Cells were treated
with 0.1% DMSO as vehicle control and with 100 nM VZ185 and 100
nM cisVZ185 as negative control. Cells were incubated at 37 °C and 5%
CO2 for 4 h before harvesting. Cells were washed twice with DPBS
(Gibco) and lysed with 0.5 mL of 100 mMTris, pH 8.0, 4% (w/v) SDS,
supplemented with cOmplete Mini EDTA-free protease inhibitor
cocktail (Roche). Lysates were sonicated (2 × 10 s) and centrifuged at
14 000 rpm for 20 min at 4 °C. The supernatant fraction of the cell
extract was collected, and protein concentration was quantiﬁed by BCA
assay (Thermo Fisher Scientiﬁc). Further sample processing, digestion,
desalting, TMT 10-plex isobaric labeling were performed as previously
described.5 After labeling, the peptides from the 9 samples were pooled
together in equal proportion. The pooled sample was fractionated into
20 discrete fractions using high pH reverse-phase chromatography on
an XBridge peptide BEH column (130 Å, 3.5 μm, 2.1 mm × 150 mm,
Waters) on an Ultimate 3000 HPLC system (Thermo Scientiﬁc/
Dionex). A mixture of buﬀer A (10 mM ammonium formate in water,
pH 9) and B (10 mM ammonium formate in 90% CH3CN, pH 9) was
used over a linear gradient of 5% to 60% buﬀer B over 60 min at a ﬂow
rate of 200 μL/min. The peptides eluted from the column were
collected in 80 fractions before concatenation into 20 fractions based on
the UV signal of each fraction. All the fractions were dried in a Genevac
EZ-2 concentrator and resuspended in 1% formic acid for MS analysis.
nLC−MS/MS Analysis.The fractions were analyzed sequentially on a
Q Exactive HF hybrid quadrupole-Orbitrap mass spectrometer
(Thermo Scientiﬁc) coupled to an UltiMate 3000 RSLCnano
UHPLC system (Thermo Scientiﬁc) and EasySpray column (75 μm
× 50 cm, PepMap RSLCC18 column, 2 μm, 100 Å, Thermo Scientiﬁc).
A mix of buﬀer A (0.1% formic acid in H2O) and B (0.08% formic acid
in 80% CH3CN) was used over a linear gradient from 5% to 35% buﬀer
B over 125 min using a ﬂow rate of 300 nL/min. Column temperature
was set at 50 °C. The Q Exactive HF hybrid quadrupole-Orbitrap mass
spectrometer was operated in data dependent mode with a single MS
survey scan from 335 to 1600 m/z followed by 15 sequential m/z
dependent MS2 scans. The 15 most intense precursor ions were
sequentially fragmented by higher energy collision dissociation (HCD).
The MS1 isolation window was set to 0.7 Da and the resolution set at
120 000. MS2 resolution was set at 60 000. The AGC targets for MS1
and MS2 were set at 3e6 ions and 1e5 ions, respectively. The
normalized collision energy was set at 32%. The maximum ion injection
times for MS1 and MS2 were set at 50 and 200 ms, respectively.
Peptide and Protein Identiﬁcation and Quantiﬁcation. The raw
MS data ﬁles for all 20 fractions were merged and searched against the
Uniprot-sprot-Human-Canonical database by Maxquant software
1.6.0.16 for protein identiﬁcation and TMT reporter ion quantitation.
The identiﬁcations were based on the following criteria: enzyme used
trypsin/P; maximum number of missed cleavages equal to 2; precursor
mass tolerance equal to 10 ppm; fragment mass tolerance equal to 20
ppm. Variable modiﬁcations: oxidation (M), acetyl (N-term),
deamidation (NQ), Gln→ pyro-Glu (QN-term). Fixed modiﬁcations:
carbamidomethyl (C). The data were ﬁltered by applying a 1% false
discovery rate followed by exclusion of proteins with less than two
unique peptides. Quantiﬁed proteins were ﬁltered if the absolute fold-
change diﬀerence between the three DMSO replicates was ≥1.5.
Protein Expression and Puriﬁcation. Human proteins VHL
(UniProt accession number P40337), ElonginC (Q15369), and
ElonginB (Q15370) and the bromodomain (residues 134−239) for
BRD9 (Q9H8M2) were used for all protein expression. His6-tagged
constructs were transformed into Escherichia coli BL21(DE3), and
expression was induced by the addition of isopropyl β-D-1-
thiogalactopyranoside (IPTG). E. coli cells were lysed using a pressure
cell homogenizer (Stansted Fluid Power); lysates were clariﬁed by
centrifuge and loaded onto a HisTrap FF aﬃnity column (GE
Healthcare). Following elution, His-tags were removed with TEV
protease and samples were loaded onto a second Ni aﬃnity column to
obtain tag-free protein. Following dialysis in a low-salt buﬀer, BRD9
bromodomain and VCB complex proteins were further puriﬁed using
cation exchange (Resource S; GE Healthcare) or anion exchange
(Resource Q; GE Healthcare) chromatography, respectively. This was
followed by a ﬁnal polish by size-exclusion chromatography using a
Superdex-75 16/600 column (GE Healthcare) equilibrated with 20
mM HEPES, pH 7.5, 100 mM sodium chloride, and 1 mM TCEP.
Crystallization and Structure Solution of BRD9 Bromodo-
main Binary Complex. The binary complex of Brd9-BD:5 was
generated by incubating 500 μM Brd9 bromodomain with 750 μM
compound 5 (from a 100 mM stock in DMSO). Crystals were grown
using the hanging-drop vapor diﬀusion method by mixing equal
volumes of binary complex solution and a crystallization solution
containing 24% PEG 3350 and 0.2 M NH4F. Small needle crystals
appeared within 48 h but took approximately 2 weeks to reach a suitable
size for harvesting. Crystals were ﬂash-frozen in liquid nitrogen using
20% ethylene glycol in liquor solution as a cryoprotectant. Diﬀraction
data were collected at Diamond Light Source beamline I24 using a
Pilatus 6M-F detector at a wavelength of 0.98962 Å. Data were indexed
and integrated using XDS,78 and scaling and merging were performed
with AIMLESS79 in CCP4i.80 The structure was solved by molecular
replacement using MOLREP81 and a search model derived from a
BRD9 bromodomain structure (PDB entry 5I40). The initial model
underwent iterative rounds of model building and reﬁnement with
COOT82 and REFMAC5,83 respectively. Compound 5 geometry
restraints for reﬁnement were prepared with the PRODRG84 server.
Model geometry and steric clashes were validated using the
MOLPROBITY server;85 Ramachandran plots indicate that 97.7% of
backbone torsion angles are in the favored region and there are no
outliers. The structure has been deposited in the Protein Data Bank
(PDB) with accession code 6HM0; data collection and reﬁnement
statistics are presented in Supporting Information Table S1.
AlphaLISA Proximity Assay. All assays were performed at room
temperature in 384-well plates with a ﬁnal assay volume of 25 μL per
well, as described previously.5 All reagents were prepared as 5× stocks
diluted in 50 mM HEPES, pH 7.5, 100 mM NaCl, 0.1% (w/v) bovine
serum albumin, and 0.02% (w/v) 3-[(cholamidopropyl)dimethyl-
ammonio]-1-propanesulfonate (CHAPS). Plates were sealed by
transparent ﬁlm and brieﬂy centrifuged at 100g between additions of
reagents. Biotinylated VCB (100 nM ﬁnal) and His6-BRD9-bromodo-
main (100 nM ﬁnal) were incubated with a range of PROTAC
concentrations (0.5−2000 nM; two-in-one serial dilution) for 1 h.
Streptavidin-coated donor beads and nickel chelate acceptor beads
(PerkinElmer) were added to a ﬁnal concentration of 10 μg mL−1, and
plates were incubated for another hour. Plates were read on a
PHERAstar FS (BMG Labtech) using an optic module with an
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excitation wavelength of 680 nm and emission wavelength of 615 nm.
Intensity values were plotted against PROTAC concentration on a log10
scale using GraphPad Prism, version 7. To obtain biotinylated-VCB,
protein was mixed with EZ-link NHS-PEG4-biotin (Thermo Scientiﬁc)
in a 1:1 molar ratio and incubated at room temperature for 1 h. The
reaction was quenched using 1 M Tris-HCl, pH 7.5, and unreacted
NHS-biotin was removed with a PD-10 MiniTrap desalting column
(GE Healthcare) equilibrated with 20 mM HEPES, pH 7.5, 150 mM
NaCl, and 1 mM DTT.
Fluorescence Polarization. All measurements were taken using a
PHERAstar FS (BMG LABTECH) with ﬂuorescence excitation and
emission wavelengths (λ) of 485 and 520 nm, respectively. FP
competitive binding assays were run in triplicate in 384-well plates
(Corning 3575) using a total well volume of 15 μL (ref 63). Each well
solution contained 15 nM VCB protein, 10 nM FAM-labeled HIF-1α
peptide (FAM-DEALAHypYIPMDDDFQLRSF, Kd = 3 nM as
measured by a direct FP titration), and decreasing concentrations of
PROTAC (14-point serial 2-fold dilutions starting from 50 μM
PROTAC) or PROTAC:bromodomain (14-point serial 2-fold
dilutions starting from 50 μM PROTAC:100 μM bromodomain into
wells containing an additional 1 μM bromodomain) in 100 mM Bis-
Tris propane, 100 mM NaCl, 1 mM TCEP, pH 7, with a ﬁnal DMSO
concentration of 1%. Control wells containing VCB and peptide with
no compound (zero displacement), or peptide in the absence of protein
(maximum displacement), were also included. Control values were
used to obtain the percentage of displacement which was graphed
against log[PROTAC]. Average IC50 values and the standard error of
the mean (SEM) were determined for each titration using Prism 7.
Dissociation constantsKd were back-calculated from the measured IC50
values using a displacement binding model, as described previously.68
Isothermal Titration Calorimetry. ITC experiments were
performed in an ITC200 microcalorimeter (GE Healthcare) as
described previously.5 Titrations were carried out at 25 °C while
stirring at 750 rpm and were performed as reverse mode (protein in the
syringe and the ligand in the cell). Compounds were diluted in ITC
buﬀer (20 mM Bis-Tris propane, 100 mM NaCl, 1 mM tris(2-
carboxyethyl)phosphine (TCEP), pH 7.5) from 10 mM DMSO stock
solutions to a ﬁnal concentration of 20 μM (0.2% DMSO). Each run
consisted of 19 injections of 2 μL of protein solution (ITC buﬀer with
0.2% DMSO) at a rate of 0.5 μL/s at 120 s time intervals. An initial
injection of 0.4 μL was made and discarded during data analysis. BRD9
bromodomain (200 μM, in the syringe) was ﬁrst titrated into the
PROTAC (20 μM, in the cell); at the end of the titration, the excess of
solution was removed from the cell and the syringe was washed and
dried. VCB complex (168 μM, in the same buﬀer) was loaded in the
syringe and titrated into the complex PROTAC-bromodomain. The
concentration of the complex in the cell (C) after the ﬁrst titration (16.8
μM), was calculated as follows:
=
+
C
C V
V V
0 cell
cell inj
where C0 is the initial concentration of the PROTAC in the cell (20
μM), Vcell is the volume of the sample cell (200.12 μL), and Vinj is the
volume of titrant injected during the ﬁrst titration (38.4 μL). Titrations
for the binary complex PROTAC-VCB were performed by ﬁrst adding
buﬀer (38.4 μL) to the solution of PROTAC (20 μM, in the cell) by a
single ITC injection. After removal of the excess solution from the cell,
VCB complex (168 μM, in the same buﬀer) was loaded into the
(washed and dried) syringe and titrated into the diluted PROTAC
solution. The data were ﬁtted to a single binding-site model using the
MicroCal PEAQ-ITC analysis software provided by the manufacturer
to obtain the stoichiometry n, the dissociation constant Kd, and the
enthalpy of binding ΔH.
Live Cell Kinetic Analysis of BRD7 and BRD9 Degradation.
HEK293 cells stably expressing LgBiT protein cultured in DMEM
(Gibco) supplemented with 10% fetal bovine serum (Seradigm) and
maintained at 37 °C and 5% CO2 were genome-edited using CRISPR/
Cas9 to generate endogenous HiBiT-BRD7 or HiBiT-BRD9 fusions.
Clonal populations were isolated, and cells were plated in 96-well tissue
culture plates at a density of 2 × 104 cells per well in 100 μL of growth
medium. Following overnight incubation at 37 °C and 5%CO2medium
was replaced with CO2-independent medium (Gibco) containing 20
μM Endurazine, an extended time-released substrate (Promega), and
plates were incubated at 37 °C, 5%CO2, for 2.5 h before addition of a 3-
fold serial dilution of 1 μM ﬁnal concentration VZ185 compound.
Plates retaining the plate lids were then read every 5 min for a period of
24 h on a GloMax Discover (Promega) set to 37 °C. Degradation traces
for each concentration were plotted in GraphPad Prism, and the
degradation portion of each curve was ﬁtted to a one-component
exponential decay model to obtain degradation parameters, rate, and
Dmax, as previously described.
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NanoBRET Ubiquitination of BRD7 and BRD9. Clonal
populations of edited HEK293 cells expressing HiBiT-BRD7 or
HiBiT-BRD9 were plated in tissue 96-well tissue culture plates at a
density of 2 × 104 cells per well in 100 μL of growth medium and
incubated overnight at 37 °C, 5% CO2. Following treatment with 1 μM
VZ185 for the indicated time frames, medium was replaced with Opti-
MEM (Gibco) containing 200 μg/mL digitonin, 1:200 dilution of
primary anti-Ub antibody (Enzo Life Sciences, BML-PW8810), 1:500
dilution of secondary anti-mouse Alexa 594 antibody (Cell Signaling
Technologies, 8890), and 20 μM NanoGlo (Promega) substrate.
Additional control wells received no antibodies (control for back-
ground NanoBRET) or no primary antibody (control for speciﬁcity).
Plates were placed on an orbital shaker for 10 min, and NanoBRET
measurements were collected on a CLARIOstar (BMG Labtech).
Background subtracted NanoBRET ratios were generated by
calculating the ratios of acceptor signal to donor signal in both the
presence and absence of the Alexa594 antibody and computing the
diﬀerence. Background subtracted BRET ratios were expressed in
milliBRET units by multiplying by 1000.
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Molecular formula strings (CSV)
Proteomics raw data (XLS)
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Atomic coordinates and structure factors for BRD9-BD:5 have
been deposited to the Protein Data Bank (PDB) under accession
number 6HM0. Authors will release the atomic coordinates and
experimental data upon article publication.
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Seo, H.-S.; Dastjerdi, S.; Wühr, M.; Dhe-Paganon, S.; Armstrong, S. A.;
Bradner, J. E. Degradation of the BAF Complex Factor BRD9 by
Heterobifunctional Ligands. Angew. Chem. 2017, 129 (21), 5832−
5837.
(19) Gechijian, L. N.; Buckley, D. L.; Lawlor, M. A.; Reyes, J. M.;
Paulk, J.; Ott, C. J.; Winter, G. E.; Erb, M. A.; Scott, T. G.; Xu, M.; Seo,
H. S.; Dhe-Paganon, S.; Kwiatkowski, N. P.; Perry, J. A.; Qi, J.; Gray, N.
S.; Bradner, J. E. Functional TRIM24 Degrader via Conjugation of
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.8b01413
J. Med. Chem. XXXX, XXX, XXX−XXX
Y
Ineffectual Bromodomain and VHL Ligands. Nat. Chem. Biol. 2018, 14
(4), 405−412.
(20) Schiedel, M.; Herp, D.; Hammelmann, S.; Swyter, S.; Lehotzky,
A.; Robaa, D.; Olah́, J.; Ovad́i, J.; Sippl, W.; Jung, M. Chemically
Induced Degradation of Sirtuin 2 (Sirt2) by a Proteolysis Targeting
Chimera (PROTAC) Based on Sirtuin Rearranging Ligands (SirReals).
J. Med. Chem. 2018, 61 (2), 482−491.
(21) Bassi, Z. I.; Fillmore,M. C.;Miah, A. H.; Chapman, T. D.;Maller,
C.; Roberts, E. J.; Davis, L. C.; Lewis, D. E.; Galwey, N. W.;
Waddington, K. E.; Parravicini, V.; Macmillan-Jones, A. L.; Gongora,
C.; Humphreys, P. G.; Churcher, I.; Prinjha, R. K.; Tough, D. F.
Modulating PCAF/GCN5 Immune Cell Function Through a
PROTAC Approach. ACS Chem. Biol. 2018, 13 (10), 2862−2867.
(22) Lai, A. C.; Toure, M.; Hellerschmied, D.; Salami, J.; Jaime-
Figueroa, S.; Ko, E.; Hines, J.; Crews, C. M. Modular PROTACDesign
for the Degradation of Oncogenic BCR-ABL. Angew. Chem., Int. Ed.
2016, 55 (2), 807−810.
(23) Huang, H.-T.; Dobrovolsky, D.; Paulk, J.; Yang, G.; Weisberg, E.
L.; Doctor, Z. M.; Buckley, D. L.; Cho, J.-H.; Ko, E.; Jang, J.; Shi, K.;
Choi, H. G.; Griffin, J. D.; Li, Y.; Treon, S. P.; Fischer, E. S.; Bradner, J.
E.; Tan, L.; Gray, N. S. A Chemoproteomic Approach to Query the
Degradable Kinome Using a Multi-Kinase Degrader. Cell Chem. Biol.
2018, 25 (1), 88−99.
(24) Crew, A. P.; Raina, K.; Dong, H.; Qian, Y.; Wang, J.; Vigil, D.;
Serebrenik, Y. V.; Hamman, B. D.; Morgan, A.; Ferraro, C.; Siu, K.;
Neklesa, T. K.; Winkler, J. D.; Coleman, K. G.; Crews, C. M.
Identification and Characterization of Von Hippel-Lindau-Recruiting
Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding
Kinase 1. J. Med. Chem. 2018, 61 (2), 583−598.
(25) Olson, C. M.; Jiang, B.; Erb, M. A.; Liang, Y.; Doctor, Z. M.;
Zhang, Z.; Zhang, T.; Kwiatkowski, N.; Boukhali, M.; Green, J. L.; Haas,
W.; Nomanbhoy, T.; Fischer, E. S.; Young, R. A.; Bradner, J. E.; Winter,
G. E.; Gray, N. S. Pharmacological Perturbation of CDK9 Using
Selective CDK9 Inhibition or Degradation. Nat. Chem. Biol. 2017, 14
(2), 163−170.
(26) Robb, C. M.; Contreras, J. I.; Kour, S.; Taylor, M. A.; Abid, M.;
Sonawane, Y. A.; Zahid, M.; Murry, D. J.; Natarajan, A.; Rana, S.
Chemically Induced Degradation of CDK9 by a Proteolysis Targeting
Chimera (PROTAC). Chem. Commun. 2017, 53 (54), 7577−7580.
(27) Shibata, N.; Nagai, K.; Morita, Y.; Ujikawa, O.; Ohoka, N.;
Hattori, T.; Koyama, R.; Sano, O.; Imaeda, Y.; Nara, H.; Cho, N.; Naito,
M. Development of Protein Degradation Inducers of Androgen
Receptor by Conjugation of Androgen Receptor Ligands and Inhibitor
of Apoptosis Protein Ligands. J. Med. Chem. 2018, 61 (2), 543−575.
(28) Salami, J.; Alabi, S.; Willard, R. R.; Vitale, N. J.; Wang, J.; Dong,
H.; Jin, M.; McDonnell, D. P.; Crew, A. P.; Neklesa, T. K.; Crews, C. M.
Androgen Receptor Degradation by the Proteolysis-Targeting Chimera
ARCC-4 Outperforms Enzalutamide in Cellular Models of Prostate
Cancer Drug Resistance. Commun. Biol. 2018, 1, 100.
(29) Maniaci, C.; Hughes, S. J.; Testa, A.; Chen, W.; Lamont, D. J.;
Rocha, S.; Alessi, D. R.; Romeo, R.; Ciulli, A. Homo-PROTACs:
Bivalent Small-Molecule Dimerizers of the VHL E3 Ubiquitin Ligase to
Induce Self-Degradation. Nat. Commun. 2017, 8 (1), 830.
(30) Steinebach, C.; Lindner, S.; Udeshi, N. D.; Mani, D. C.; Kehm,
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